var title_f26_52_27456="Newborn with natal teeth";
var content_f26_52_27456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Natal teeth radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This radiograph of a newborn with natal teeth confirms they are the normal primary central incisors and not supernumerary teeth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright &copy; WB Saunders 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27456=[""].join("\n");
var outline_f26_52_27456=null;
var title_f26_52_27457="Arthroscopic surgery PI";
var content_f26_52_27457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Arthroscopic surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 594px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arthroscopic surgery can be used to repair or replace joints in the knee, shoulder, and hip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27457=[""].join("\n");
var outline_f26_52_27457=null;
var title_f26_52_27458="Livedoid vasculopathy - close view";
var content_f26_52_27458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Livedoid vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Punched out ulcers and atrophic white scars on the lower legs are common features of livedoid vasculopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27458=[""].join("\n");
var outline_f26_52_27458=null;
var title_f26_52_27459="Rocuronium: Patient drug information";
var content_f26_52_27459=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rocuronium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     see \"Rocuronium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     see \"Rocuronium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zemuron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rocuronium Bromide Injection;",
"     </li>",
"     <li>",
"      Zemuron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles during surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles while on a breathing machine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rocuronium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12110 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27459=[""].join("\n");
var outline_f26_52_27459=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219069\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219070\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019843\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019845\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019844\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019848\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019849\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019851\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019847\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019853\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=related_link\">",
"      Rocuronium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=related_link\">",
"      Rocuronium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_52_27460="Liposomal bupivacaine: Drug information";
var content_f26_52_27460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal bupivacaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/26/18851?source=see_link\">",
"    see \"Liposomal bupivacaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14187699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exparel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13321184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Nonopioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14080900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Postoperative analgesia:",
"     </b>",
"     Infiltration (local): Dose is based on surgical site and volume required to cover the area (in general, the maximum total dose is 266 mg).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bunionectomy: 7 mL into the tissues surrounding the osteotomy and 1 mL into the subcutaneous tissue of the surgical site (total dose = 8 mL [106 mg])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemorrhoidectomy: 30 mL (20 mL vial diluted with 10 mL NS) divided and administered as 6 injections of 5 mL each (total dose = 30 mL [266 mg])",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14080902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, renal impairment may reduce bupivacaine elimination increasing systemic exposure and the risk of adverse effects or toxicities; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14080901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, moderate-to-severe impairment may reduce bupivacaine metabolism increasing systemic exposure and the risk of adverse effects or toxicities; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14080946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exparel&trade;: 1.3% [13.3 mg/mL] (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14080936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14080903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For local infiltration use only.  Invert vial several times prior to withdrawing contents (resuspends particles). Administer using a &ge;25 gauge needle. May administer &ge;20 minutes after local lidocaine administration (if applicable). Allow topical antiseptics (eg. povidone iodine) applied to surgical site to dry prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bunionectomy: Infiltrate into the tissues surrounding the osteotomy and into the subcutaneous tissue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemorrhoidectomy: Visualize the anal sphincter as a clock face and slowly infiltrate each aliquot (5 mL) of the diluted 20 mL vial into each of the even numbers.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14080884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13321010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Injected into the surgical site (eg, bunionectomy, hemorrhoidectomy) to provide  postoperative analgesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13321183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bupivacaine may be confused with mepivacaine, ropivacaine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bupivacaine liposomal may be confused with conventional bupivacaine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bupivacaine liposomal may be confused with propofol due to similar white, milky appearance.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14080873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Nausea (2% to 40%), vomiting (28%), constipation (2% to &ge;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (2% to 10%), peripheral edema (2% to 10%), tachycardia (4%), bradycardia (2%), syncope (&lt;2%), edema (&lt;2%), hypertension (&lt;2%), pallor (&lt;2%), palpitation (&lt;2%), sinus bradycardia (&lt;2%), supraventricular extrasystoles (&lt;2%), ventricular extrasystoles (&lt;2%), ventricular tachycardia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (2% to 10%), dizziness (6%), somnolence (2% to 5%), headache (4%), fever (2%), hypoesthesia (2%), agitation (&lt;2%), anxiety (&lt;2%), chills (&lt;2%), confusion (&lt;2%), depression (&lt;2%), pain (&lt;2%), restlessness (&lt;2%), tremor (&lt;2%), lethargy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3%), erythema (&lt;2%), hyperhidrosis (&lt;2%), pruritic rash (&lt;2%), urticaria (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary incontinence (&lt;2%), urinary retention (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (hemorrhagic, postoperative; 2% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (3%), ALT increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Incision site edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (2% to 10%), muscle spasm (2% to 10%), neck pain (&lt;2%), paresthesia (&lt;2%), weakness (&lt;2%), chondrolysis (continuous intra-articular administration; develops months after surgery)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Tinnitus (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Apnea (&lt;2%), hypoxia (&lt;2%), laryngospasm (&lt;2%), respiratory depression/failure (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Feeling of warmth (2%), fungal infection (2%), anaphylactoid reactions (&lt;2%), diaphoresis (&lt;2%), hypersensitivity reactions (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Cardiac arrest, heart block",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Persistent anesthesia, paralysis, seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Pupillary constriction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14080834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obstetrical paracervical block anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14080835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Bupivacaine-containing products have been associated with rare occurrences of arrhythmias, cardiac arrest, and death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: CNS effects (including stimulation and/or depression) have been reported with bupivacaine-containing products; monitor for CNS-related changes or alterations in consciousness.  Additionally, use of local anesthetics have been associated with rare occurrences of localized neurological toxicity (numbness, weakness, paralysis), which may be irreversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Systemic hypersensitivity reactions (eg, angioedema, urticaria) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease including patients with hypotension or heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Other local anesthetics: Wait at least 96 hours after administration before administering other bupivacaine-containing products. Wait at least 20 minutes after administration of locally administered lidocaine before administering bupivacaine (liposomal).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular, epidural, intrathecal, intra-articular, and regional nerve block injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should not be used to provide presurgical anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Exparel&trade; and other bupivacaine products are not interchangeable due to differences in formulation and indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14080937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14080832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects. Use during pregnancy only if the benefits justify the risk to the fetus. Use in obstetrical paracervical block anesthesia is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14080833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Exparel Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.3% (20 mL): $342.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14080938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, state of consciousness; signs of CNS toxicity, pain relief.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14080885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14080887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Local: ~24 hours; Systemic: 96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via conjugation; major metabolite pipecoloxylidine (PPX; inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Apparent: 24-34 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Bunionectomy: 2 hours: Hemorrhoidectomy: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~6% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27460/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golf M, Daniels SE, and Onel E, \"A Phase 3, Randomized, Placebo-Controlled Trial of Depofoam&reg; Bupivacaine (Extended-Release Bupivacaine Local Analgesic) in Bunionectomy,\"",
"      <i>",
"       Adv Ther",
"      </i>",
"      , 2011, 28(9):776-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27460/abstract-text/21842428/pubmed\" id=\"21842428\" target=\"_blank\">",
"        21842428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gorfine SR, Onel E, Patou G, et al, \"Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,\"",
"      <i>",
"       Dis Colon Rectum",
"      </i>",
"      , 2011, 54(12):1552-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27460/abstract-text/22067185/pubmed\" id=\"22067185\" target=\"_blank\">",
"        22067185",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27460/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17057 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27460=[""].join("\n");
var outline_f26_52_27460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14187699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321184\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080900\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080902\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080901\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080946\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080936\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080903\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080884\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321010\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321183\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080873\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080834\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080835\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080937\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080832\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080833\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322920\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080938\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080885\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080887\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17057|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/26/18851?source=related_link\">",
"      Liposomal bupivacaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_52_27461="Laparoscopic salpingectomy caut";
var content_f26_52_27461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Technique of laparoscopic total salpingectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Bipolar cautery is used to fulgurate the tube at its insertion into the uterus; (B) Pre-tied surgical loops are placed over the fallopian tube; (C) Fallopian tube is excised.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27461=[""].join("\n");
var outline_f26_52_27461=null;
var title_f26_52_27462="Nitrofurantoin-induced pulmonary injury";
var content_f26_52_27462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nitrofurantoin-induced pulmonary injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Justus de Zeeuw, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Jochen Schumacher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Adrian G Gillissen, PhD, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27462/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/52/27462/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     Nitrofurantoin",
"    </a>",
"    is an antibacterial agent frequently used in the management of urinary tract infections (UTIs). This antimicrobial drug is generally used in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The short-term prophylaxis of infections acquired by invasive urologic diagnostic procedures and operations",
"     </li>",
"     <li>",
"      The long-term prevention of recurrent UTIs",
"     </li>",
"     <li>",
"      The treatment of acute or recurrent cystitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common adverse reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    (apart from turning the urine color a harmless brown) are nausea (8 percent), headache (6 percent), and flatulence (1.5 percent). Among the rare adverse reactions (&lt;1 percent), pulmonary injury is the most severe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary toxicity due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    has two main presentations: an acute onset approximately nine days after a short course of therapy and a chronic onset developing after several months or years of nitrofurantoin therapy. The clinical manifestations, diagnosis, and treatment of nitrofurantoin toxicity will be reviewed here. Pulmonary reactions due to other drugs are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients (85 to 95 percent) who present with pulmonary reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    are women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/2\">",
"     2",
"    </a>",
"    ]. This is related to the greater susceptibility of women to recurrent urinary tract infections, so that women are more often exposed to long-term nitrofurantoin than are men. The median age among those presenting with the acute or chronic forms of the illness is approximately 60 and 70 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute form of the illness is the most common pulmonary reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    . In one study, for example, an acute or chronic reaction was observed in 83, 4, and 13 percent of affected patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. Cases of fatal nitrofurantoin-induced pulmonary injury have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    -induced pulmonary injury decreased from a high in the 1960s to a low in the 1980s. However, this condition is on the increase again, as the drug regains popularity as a urinary antiseptic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/6-11\">",
"     6-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic pulmonary reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    are caused by different mechanisms. In acute pulmonary reactions, histopathologic examination of the lung typically reveals vasculitis, mild interstitial inflammation, eosinophilia, reactive type II pneumocytes, focal hemorrhage, and (in some cases) small organizing microthrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=see_link\">",
"     \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, a diffuse interstitial fibrosis is observed in chronic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/13\">",
"     13",
"    </a>",
"    ]. Vascular sclerosis, fibrosis and thickening of the alveolar septa, and interstitial inflammation are common features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. A pattern of organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia) also has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute and chronic forms of lung injury result from different pathogenic mechanisms. The acute form is a hypersensitivity reaction (type I or III). By comparison, the chronic form may be either a cell-mediated or toxic response. In vitro studies suggest that toxic products produced by drug metabolites may cause injury in the presence of oxygen and lung microsomes. This mechanism of lung damage may be similar to that observed with the herbicide paraquat [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11991?source=see_link\">",
"     \"Paraquat poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    do not appear to be dose related, and can present with a range of symptoms. Concomitant hepatic toxicity has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently reported symptoms of an acute hypersensitivity reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    are fever exceeding 37.9&ordm;C (82 percent), dyspnea (60 percent), irritating cough (43 percent), and rash (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Chest pain and cyanosis may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A delay is observed between the initial exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    and the acute onset of symptoms. As an example, one study of 81 patients with an acute hypersensitivity reaction noted a mean duration of approximately 9 days between drug exposure and pulmonary symptoms among the 66 patients with pulmonary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. Approximately 80 percent of patients note the abrupt onset of symptoms. In contrast, symptoms recur in a much shorter period (generally within 24 hours) following rechallenge with nitrofurantoin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of chronic pulmonary reactions develop after several months of low dose treatment, respectively. The most frequently reported symptoms are dyspnea (73 percent), dry cough (63 percent), and fatigue (37 percent). Symptoms are usually less intense than in acute reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. Fever is uncommon in patients with the chronic form of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crepitant crackles (especially over the basal lung fields) are heard in most patients; these findings may be accompanied by dry crackles in those with severe chronic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients exhibit some degree of pulmonary dysfunction on pulmonary function testing. In one study, for example, all patients had a moderate impairment of the gas transfer factor (47 to 78 percent of the reference value) when examined within two weeks after admission to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. No reduction in FEV1 or vital capacity was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. In a second report, half of patients with chronic disease had a restrictive pattern of pulmonary dysfunction with reduced lung volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with acute reactions, the most commonly reported laboratory findings are eosinophilia (83 percent), leukocytosis (52 percent), and an elevated erythrocyte sedimentation rate (over 50",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    in 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. By comparison, findings noted in the chronic group include elevated serum gamma globulins (80 percent), eosinophilia (44 percent), elevated serum transaminases (37 percent), and increased erythrocyte sedimentation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Positive antinuclear antibody (60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ] and rheumatoid factor tests are also found among those in the chronic group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic abnormalities are observed in the vast majority of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50491 \" href=\"UTD.htm?42/44/43712\">",
"     image 1",
"    </a>",
"    ). In one study, one-third of patients were noted to have diffuse parenchymal changes consisting of streaky or mottled shadowing located predominantly in the lower lung zones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. Parenchymal changes were almost always bilateral. Pleural effusions, which were predominantly unilateral, were accompanied by parenchymal changes.",
"   </p>",
"   <p>",
"    In another study, all patients with chronic reactions had pulmonary parenchymal opacities on chest radiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3\">",
"     3",
"    </a>",
"    ]. Pleural effusions are rare in patients with the chronic form of the disease.",
"   </p>",
"   <p>",
"    The CT findings of chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    -induced lung disease were evaluated in a retrospective review of 18 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/2\">",
"     2",
"    </a>",
"    ]. Bilateral areas of ground glass attenuation with no dominant pattern of zonal distribution were the most common pattern. In contrast to patients with idiopathic pulmonary fibrosis, irregular linear opacities were uncommon in patients with nitrofurantoin-induced lung disease. Honeycombing is typically absent, although it was reported in a single case [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results obtained with bronchoalveolar lavage (BAL) in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    -induced pulmonary injury are not specific. Findings include lymphocytosis, neutrophilia, and eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an acute reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    can be established solely by the characteristic symptoms and the duration of time between drug exposure and symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Common alternative diagnoses to be evaluated in the differential are heart failure, bacterial or atypical pneumonia, exacerbation of asthma, myocardial infarction, pericarditis, and influenza. Sputum culture and mycoplasma titer may be helpful to rule out infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the acute form, symptoms should resolve in 24 to 48 hours after discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    therapy. Failure of resolution should lead to more invasive testing.",
"   </p>",
"   <p>",
"    Chronic lung toxicity can be recognized by a restrictive pattern in lung function testing and by bilateral reticular and ground glass opacities on chest radiography, combined with a compatible history of exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    . It may take weeks to months for the symptoms and radiographic changes to regress after cessation of nitrofurantoin.",
"   </p>",
"   <p>",
"    The differential diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    pulmonary toxicity includes infection, lymphangitic tumor, the idiopathic interstitial pneumonias and, when the antinuclear antibody or rheumatoid factor tests are positive, development of connective tissue disease with lung involvement. However, the presence of autoantibodies may just be a manifestation of the reaction to nitrofurantoin. Depending on the severity of disease and degree of concern about infection or tumor, further evaluation via bronchoscopy with bronchoalveolar lavage, or a transbronchial or open lung biopsy may be needed to rule out alternative diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung biopsy in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    pulmonary toxicity typically reveals interstitial inflammation or fibrosis, while cultures for bacteria, fungi, and acid-fast bacteria are negative. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    therapy generally results in the regression of symptoms; however, weeks to months may be required for recovery. Oral glucocorticoids are sometimes given as a therapeutic measure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, the benefit of glucocorticoid therapy has never been proven, and even severe pulmonary toxicity may resolve without the use of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/21\">",
"     21",
"    </a>",
"    ]. Only single case reports have demonstrated rapid improvement after initiation of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/7,12,13,15\">",
"     7,12,13,15",
"    </a>",
"    ]. We typically do",
"    <strong>",
"     not",
"    </strong>",
"    use glucocorticoids for treatment of adverse reactions to nitrofurantoin, unless the patient has severe respiratory compromise and infection has been carefully excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/2\">",
"     2",
"    </a>",
"    ]. When needed, a prednisone-equivalent dose of 20 to 40 mg per day is given with slow tapering over several months. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis is good if the condition is recognized early and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    exposure is stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/12\">",
"     12",
"    </a>",
"    ]. Most patients with an acute pulmonary reaction recover within 15 days. One study found that 47 percent of patients were symptom-free within one day, and 88 percent within three days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with chronic reactions, recovery took from 2 weeks to 3 months, although mild fibrotic changes persisted in two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"     4",
"    </a>",
"    ]. Resolution of advanced-appearing interstitial disease on CT has been reported following discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/7,22\">",
"     7,22",
"    </a>",
"    ]; however, fatalities have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27462/abstract/3-5,23,24\">",
"     3-5,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6718247\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary toxicity due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      has two main presentations: an acute onset approximately nine days after a short course of therapy and a chronic onset developing after several months of nitrofurantoin therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequently reported symptoms of an acute hypersensitivity reaction are fever, dyspnea, and an irritating cough; rash is occasionally seen. The presentation of chronic toxicity includes a more insidious onset of dyspnea, dry cough, and fatigue without fever. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings are generally nonspecific in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      -induced pulmonary toxicity. Peripheral blood eosinophilia is common among patients with acute reactions. Chronic reactions are associated with elevations in serum gamma globulin, serum transaminases, and erythrocyte sedimentation rate, and also positive antinuclear antibody and rheumatoid factor tests. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of an acute reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      can be established by the combination of exposure to nitrofurantoin, the characteristic time course of onset and pattern of symptoms, and compatible laboratory tests. Prompt resolution following discontinuation of nitrofurantoin further supports the diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of chronic pulmonary toxicity is based on the history of long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      therapy and the absence of another explanation for the patient&rsquo;s symptoms and radiographic abnormalities. The differential diagnosis includes the idiopathic interstitial pneumonias and, when the antinuclear antibody or rheumatoid factor tests are positive, development of connective tissue disease with lung involvement. However, positive autoantibody tests may just be a reaction to the nitrofurantoin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"       \"Interstitial lung disease in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Generally, the only treatment needed for acute pulmonary reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      is withdrawal of the drug and avoidance of rechallenge. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the majority of patients with a chronic reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      , discontinuation of nitrofurantoin results in the regression of symptoms and radiographic abnormalities, although weeks to months may be required for full symptomatic recovery; rare cases are fatal. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic glucocorticoids are occasionally administered to patients with more severe respiratory compromise, although it remains unclear how much glucocorticoids contribute to improvement beyond drug cessation alone. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/1\">",
"      Rosenow EC 3rd. The spectrum of drug-induced pulmonary disease. Ann Intern Med 1972; 77:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/2\">",
"      Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc 2005; 80:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/3\">",
"      Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976. Eur J Respir Dis 1981; 62:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/4\">",
"      Sovij&auml;rvi AR, Lemola M, Stenius B, Id&auml;np&auml;&auml;n-Heikkil&auml; J. Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis 1977; 58:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/5\">",
"      Bidad K, Harries-Jones R. Nitrofurantoin lung injury. Age Ageing 2004; 33:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/6\">",
"      Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/7\">",
"      Viejo MA, Fern&aacute;ndez Montes A, Montes JV, et al. [Rapid resolution of nitrofurantoin-induced interstitial lung disease]. Arch Bronconeumol 2009; 45:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/8\">",
"      Hage P, El Hajje MJ. Nitrofurantoin-induced desquamative interstitial pneumonitis in a 7-year-old child. Pediatr Infect Dis J 2011; 30:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/9\">",
"      Lin DC, Bhally H. Nitrofurantoin-induced interstitial lung disease. N Z Med J 2007; 120:U2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/10\">",
"      Wilkin T, Hale LS, Claiborne RA. Poor medication history plus slow symptom onset delays a diagnosis. JAAPA 2009; 22:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/11\">",
"      Mrozek N, Del&egrave;vaux I, Legendre M, et al. [Nitrofurantoin-induced lung disease: about two cases]. Rev Med Interne 2008; 29:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/12\">",
"      Robinson BW. Nitrofurantoin-induced interstitial pulmonary fibrosis. Presentation and outcome. Med J Aust 1983; 1:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/13\">",
"      Hainer BL, White AA. Nitrofurantoin pulmonary toxicity. J Fam Pract 1981; 13:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/14\">",
"      Cameron RJ, Kolbe J, Wilsher ML, Lambie N. Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. Thorax 2000; 55:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/15\">",
"      Lenci G, M&uuml;ller-Quernheim J, Lorenz J, Ferlinz R. [Pulmonary toxicity caused by nitrofurantoin]. Pneumologie 1993; 47:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/16\">",
"      Boyd MR, Catignani GL, Sasame HA, et al. Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen. Am Rev Respir Dis 1979; 120:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/17\">",
"      Peall AF, Hodges A. Concomitant pulmonary and hepatic toxicity secondary to nitrofurantoin: a case report. J Med Case Rep 2007; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/18\">",
"      Koulaouzidis A, Bhat S, Moschos J, et al. Nitrofurantoin-induced lung- and hepatotoxicity. Ann Hepatol 2007; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/19\">",
"      Williams EM, Triller DM. Recurrent acute nitrofurantoin-induced pulmonary toxicity. Pharmacotherapy 2006; 26:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/20\">",
"      Martins RR, Marchiori E, Viana SL, et al. Chronic eosinophilic pneumonia secondary to long-term use of nitrofurantoin: high-resolution computed tomography findings. J Bras Pneumol 2008; 34:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/21\">",
"      Bhullar S, Lele SM, Kraman S. Severe nitrofurantoin lung disease resolving without the use of steroids. J Postgrad Med 2007; 53:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/22\">",
"      Sheehan RE, Wells AU, Milne DG, Hansell DM. Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities. J Comput Assist Tomogr 2000; 24:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/23\">",
"      Fux R, M&ouml;rike K, Gleiter CH. [Unwanted side effects of antibacterials--a diagnostic challenge]. Dtsch Med Wochenschr 2008; 133:F4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27462/abstract/24\">",
"      Goemaere NN, Grijm K, van Hal PT, den Bakker MA. Nitrofurantoin-induced pulmonary fibrosis: a case report. J Med Case Rep 2008; 2:169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4371 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-BB0417C59D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27462=[""].join("\n");
var outline_f26_52_27462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6718247\">",
"      SUMMARY AND RECOMMENDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4371|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/44/43712\" title=\"diagnostic image 1\">",
"      Nitrofurantoin lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=related_link\">",
"      Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11991?source=related_link\">",
"      Paraquat poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_52_27463="Indications for permanent cardiac pacing";
var content_f26_52_27463=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for permanent cardiac pacing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27463/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27463/contributors\">",
"     David L Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27463/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27463/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27463/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27463/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/52/27463/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for implantation of cardiac pacemakers have been established by a task force formed jointly by the American College of Cardiology, the American Heart Association, and the Heart Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although there are occasional cases that cannot be categorized according to these guidelines, they are, for the most part, all-encompassing and have been widely endorsed. Similar and concordant guidelines have also been established by the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some indications for permanent pacing are relatively certain or unambiguous, while others require considerable expertise and judgment. It is helpful to divide the indications for pacemaker implantation into three specific categories, or classes, as defined by the",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I &mdash; Conditions in which permanent pacing is definitely beneficial, useful, and effective. In such conditions, implantation of a cardiac pacemaker is considered acceptable and necessary, provided that the condition is not due to a transient cause.",
"     </li>",
"     <li>",
"      Class II &mdash; Conditions in which permanent pacing may be indicated but there is conflicting evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      divergence of opinion; class IIA refers to conditions in which the weight of",
"      <span class=\"nowrap\">",
"       evidence/opinion",
"      </span>",
"      is in favor of",
"      <span class=\"nowrap\">",
"       usefulness/efficacy,",
"      </span>",
"      while class IIB refers to conditions in which the",
"      <span class=\"nowrap\">",
"       usefulness/efficacy",
"      </span>",
"      is less well established by",
"      <span class=\"nowrap\">",
"       evidence/opinion.",
"      </span>",
"     </li>",
"     <li>",
"      Class III &mdash; Conditions in which permanent pacing is not",
"      <span class=\"nowrap\">",
"       useful/effective",
"      </span>",
"      and in some cases may be harmful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will present a broad review of the role of pacing in a variety of different settings. The management of the specific disorders is discussed separately as is a description of the different types of pacemakers and pacing modes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the myriad of clinical situations in which permanent pacing is considered, two general factors guide many decisions: the association of symptoms with an arrhythmia and the location of the conduction abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients frequently present for consideration of pacemaker placement because of symptoms that may be due to bradyarrhythmias (eg, dizziness, lightheadedness, syncope, fatigue, and poor exercise tolerance). These patients will often have evidence of mild or intermittent sinus node dysfunction or conduction abnormalities. It is critical to attempt to establish a direct correlation between symptoms and bradyarrhythmias. This is done via a careful history and ambulatory monitoring.",
"   </p>",
"   <p>",
"    A direct correlation between symptoms and bradyarrhythmias will increase the likelihood of recommending pacemaker placement. On the other hand, failure to document such a correlation or the presence of an alternative explanation for symptoms will make pacemaker placement less likely or even contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Location of conduction abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of an atrioventricular (AV) conduction abnormality (ie, within the AV node or below the AV node in the His-Purkinje system) is an important determinant of both the probability and the likely pace of progression of conduction system disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disease within the AV node is suggested by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant PR prolongation",
"     </li>",
"     <li>",
"      Mobitz type I or AV Wenckebach",
"     </li>",
"     <li>",
"      Normal QRS complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disease below the AV node, in the His-Purkinje system, is suggested by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal or minimally prolonged PR interval",
"     </li>",
"     <li>",
"      Mobitz type II",
"     </li>",
"     <li>",
"      QRS complex abnormalities (bundle branch block",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fascicular block)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disease in the His-Purkinje system is generally considered to be less stable; as a result, permanent pacemaker placement is more likely to be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMMON INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for pacemaker implantation are sinus node dysfunction followed by AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/4\">",
"     4",
"    </a>",
"    ]. All other indications are much less common and include neurocardiogenic syncope and iatrogenic causes, eg, post-AV node ablation. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Neurocardiogenic syncope'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sinus node dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for permanent pacing in patients with sinus node dysfunction is based largely upon the correlation of bradycardia with symptoms (",
"    <a class=\"graphic graphic_table graphicRef59797 graphicRef70519 \" href=\"UTD.htm?3/46/3821\">",
"     table 1A-B",
"    </a>",
"    ). The most significant symptoms are syncope, seizures, heart failure, dizziness, and confusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Class I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions are considered class I indications for pacemaker placement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia in which symptoms are clearly related to the bradycardia (usually in patients with a heart rate below 40",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      or frequent sinus pauses).",
"     </li>",
"     <li>",
"      Symptomatic chronotropic incompetence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H4#H4\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Heart rate response to exercise'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Class II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are considered to be class II, or possible, indications for pacemaker placement in patients with sinus node dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia (heart rate &lt;40",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      in a patient with symptoms suggestive of bradycardia, but without a clearly demonstrated association between bradycardia and symptoms.",
"     </li>",
"     <li>",
"      Sinus node dysfunction in a patient with unexplained syncope.",
"     </li>",
"     <li>",
"      Chronic heart rates &lt;40",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      while awake in a minimally symptomatic patient.",
"     </li>",
"     <li>",
"      A less distinct group of patients with sinus bradycardia of lesser severity (heart rate &gt;40",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      who complain of dizziness or confusion that correlates with the slower rates. Although this group is not specifically addressed in the 2008",
"      <span class=\"nowrap\">",
"       ACC/AHA/HRS",
"      </span>",
"      guidelines, we regard them as potential candidates for pacemaker therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Drug-induced sinus node dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients will meet the above indications for pacemaker implantation due to the effects of medications that are necessary for the treatment of arrhythmias or other medical conditions. In such cases, patients should be considered to have the same indication for pacemaker implantation as those with intrinsic sinus node dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acquired AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired AV block is the second most common indication for permanent pacemaker placement (",
"    <a class=\"graphic graphic_table graphicRef81080 \" href=\"UTD.htm?23/23/23933\">",
"     table 2",
"    </a>",
"    ). Many disorders can cause acquired AV block, and these are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Class I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions represent severe conduction disease and are generally considered to be class I indications for pacing, regardless of associated symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete (third-degree) AV block",
"     </li>",
"     <li>",
"      Advanced second-degree AV block (block of two or more consecutive P waves)",
"     </li>",
"     <li>",
"      Symptomatic Mobitz I or Mobitz II second-degree AV block",
"     </li>",
"     <li>",
"      Mobitz II second-degree AV block with a widened QRS or chronic bifascicular block, regardless of symptoms",
"     </li>",
"     <li>",
"      Exercise-induced second- or third-degree AV block (in the absence of myocardial ischemia) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some controversy exists concerning asymptomatic patients with complete heart block and a structurally normal heart. The current",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines classify asymptomatic third-degree AV block with average awake ventricular rates &ge;40",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    in a patient with normal left ventricular size and function, as a class IIa indication for permanent pacemaker implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, some practitioners consider this condition a definite indication for pacemaker placement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, the current guidelines consider asymptomatic complete AV block in the setting of cardiomegaly or left ventricular dysfunction to be a class I indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Class II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with less severe forms of acquired AV block may still benefit from pacemaker placement. In such patients, determinations are often based upon correlation of bradycardia with symptoms, exclusion of other causes of symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    results of electrophysiology (EP) testing.",
"   </p>",
"   <p>",
"    Conditions in which pacemaker placement can be considered include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic Mobitz II second-degree AV block with a narrow QRS interval; patients with associated symptoms or a widened QRS interval have a class I indication for pacemaker placement.",
"     </li>",
"     <li>",
"      First-degree AV block when there is hemodynamic compromise because of effective AV dissociation secondary to a very long PR interval. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=see_link&amp;anchor=H15#H15\">",
"       \"First degree atrioventricular block\", section on 'Clinical approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bifascicular or trifascicular block associated with syncope that can be attributed to transient complete heart block, based upon the exclusion of other plausible causes of syncope, even if syncope isn't correlated with AV block (specifically ventricular tachycardia) (",
"      <a class=\"graphic graphic_table graphicRef66737 graphicRef80379 \" href=\"UTD.htm?11/48/12045\">",
"       table 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=see_link\">",
"       \"Course and treatment of chronic bifascicular block\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Drug-induced AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients will meet the above indications for pacemaker implantation due to the effects of medications that are necessary for the treatment of arrhythmias or other medical conditions. In such cases, patients should be considered to have the same indication for pacemaker implantation as those with intrinsic AV conduction disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology of atrioventricular block\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Role of EP study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of AV conduction found at EP study that are possible indications for pacemaker placement include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markedly prolonged conduction between the His bundle and the ventricle (HV interval &gt;100 msec) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pacing-induced AV block below the His bundle [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Post myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature and prognosis of conduction abnormalities associated with myocardial infarction (MI) are distinct from other forms of conduction disease. Separate criteria for pacemaker placement have been established in this setting (",
"    <a class=\"graphic graphic_table graphicRef61413 \" href=\"UTD.htm?16/41/17052\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Class I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are considered to be class I indications for pacing after myocardial infarction, regardless of symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Third-degree AV block within or below the His-Purkinje system.",
"     </li>",
"     <li>",
"      Persistent second-degree AV block in the His-Purkinje system, with bilateral bundle branch block.",
"     </li>",
"     <li>",
"      Transient advanced infranodal AV block with associated bundle branch block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic and persistent second- or third-degree AV block is also considered a class I indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Class II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following MI, persistent, asymptomatic second- or third-degree AV block at the level of the AV node is a class II indication for pacemaker placement (symptomatic block or block below the level of the AV node is a class I indication).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neurocardiogenic syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the patient with syncope can be clinically challenging. Once a diagnosis of neurocardiogenic syncope is established or suspected, effective treatment can be similarly challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of pacemakers in this disorder is limited to selected patients whose syncopal events are clearly associated with a cardioinhibitory or bradycardic event, or to those with a probable bradycardic cause and no other explanation for syncope after a thorough evaluation (",
"    <a class=\"graphic graphic_table graphicRef73219 \" href=\"UTD.htm?14/27/14780\">",
"     table 5",
"    </a>",
"    ). Pacemaker treatment is usually effective in patients with an isolated cardioinhibitory or bradycardic cause of syncope. However, since many patients have both bradycardic and vasodepressor components, some patients with an indication for pacemaker placement may not have a significant improvement in symptoms with pacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link&amp;anchor=H18#H18\">",
"     \"Reflex syncope\", section on 'Cardiac pacemakers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Class I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are considered class I indications in patients with neurocardiogenic syncope:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant carotid sinus hypersensitivity, defined by syncope and &gt;3 seconds of asystole following minimal carotid sinus massage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Class II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Situations in which pacemaker placement may be considered include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with syncope without clear provocative events and with a hypersensitive cardioinhibitory response of three seconds or longer.",
"     </li>",
"     <li>",
"      Patients with recurrent neurocardiogenic syncope associated with bradycardia documented spontaneously or at the time of tilt-table testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Congenital complete heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neuromuscular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neuromuscular diseases are associated with AV block. These include myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb's dystrophy (limb-girdle), and peroneal muscular atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"     \"Inherited syndromes associated with cardiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with these disorders have a class I indication for pacemaker placement once any evidence of second- or third-degree block develops. This is true even if the patient is asymptomatic, because there may be unpredictably rapid progression of AV conduction disease.",
"   </p>",
"   <p>",
"    Due to this potential for rapid progression, patients with these disorders are considered to have a class IIb indication for pacemaker placement even with first degree AV block, regardless of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional settings in which patients may benefit from pacemaker placement include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk patients with congenital long QT syndrome have been treated with pacemakers to prevent ventricular arrhythmias. However, most such patients are now treated with an implantable cardioverter-defibrillator, which also has pacing capability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"     \"Prognosis and management of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacing for medically refractory, symptomatic hypertrophic cardiomyopathy with significant resting or provoked LV outflow obstruction is now considered a class IIb indication and is not generally recommended (",
"    <a class=\"graphic graphic_table graphicRef80894 \" href=\"UTD.htm?38/16/39179\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT), is used to improve symptoms and survival in patients with medically refractory advanced heart failure, nonischemic or ischemic cardiomyopathy, and left ventricular dyssynchrony. The use of CRT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for pacemaker placement are the same as for other patients with one specific indication: symptomatic bradyarrhythmias or chronotropic incompetence that are not expected to resolve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link&amp;anchor=H4#H4\">",
"     \"Arrhythmias following cardiac transplantation\", section on 'Conduction disturbances'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Bradycardia-induced ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged pauses can precipitate ventricular arrhythmias. Although this phenomenon is most commonly associated with QT prolongation, it can occur in patients with a normal QT interval. Patients with pause-dependent ventricular arrhythmias, with or without QT prolongation, have an indication for pacemaker implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/1\">",
"     1",
"    </a>",
"    ]. As noted above, however, many such patients will be treated with an implantable cardioverter-defibrillator, which also has pacing capability. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Long QT syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CLASS III: PACING NOT INDICATED",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions are considered to lack adequate evidence of benefit from permanent pacing. Most of these conditions are bradyarrhythmias that are asymptomatic or due to reversible causes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syncope of undetermined etiology (",
"      <a class=\"graphic graphic_table graphicRef73219 \" href=\"UTD.htm?14/27/14780\">",
"       table 5",
"      </a>",
"      ). This may require extensive investigation, including ambulatory monitoring, neurologic evaluation, electrophysiologic testing, and perhaps tilt-table testing.",
"      <br/>",
"      <br/>",
"      Cardiac pacing may be considered if no other etiology of syncope is uncovered, and the history strongly suggests a cardiogenic origin. In such cases, the patient must understand that permanent pacing may not alleviate the symptoms, since no correlation between symptoms and rhythm has been documented. In addition, if a pacemaker is implanted because of a strong clinical suspicion that the patient's symptoms are due to a bradyarrhythmia, in the absence of any objective evidence of conduction system disease, reimbursement may be disallowed.",
"     </li>",
"     <li>",
"      Sinus bradycardia without significant symptoms.",
"     </li>",
"     <li>",
"      Sinoatrial block or sinus arrest without significant symptoms.",
"     </li>",
"     <li>",
"      Asymptomatic prolonged RR intervals with atrial fibrillation or other causes of transient ventricular pause.",
"     </li>",
"     <li>",
"      Asymptomatic bradycardia during sleep.",
"     </li>",
"     <li>",
"      Asymptomatic second-degree Mobitz I (Wenckebach) AV block.",
"     </li>",
"     <li>",
"      A hyperactive cardioinhibitory response to carotid sinus stimulation in the absence of symptoms or in the presence of vague symptoms such as dizziness, lightheadedness, or both.",
"     </li>",
"     <li>",
"      Right bundle branch block with left axis deviation without syncope or other symptoms of intermittent AV block.",
"     </li>",
"     <li>",
"      Reversible AV block, such as those associated with electrolyte abnormalities, Lyme disease, sleep apnea, enhanced vagal tone, and some cases that occur postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/5\">",
"       5",
"      </a>",
"      ]. Atrioventricular block associated with drugs such as beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      is not always reversible and can be associated with underlying conduction system disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27463/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link&amp;anchor=H11#H11\">",
"       \"Etiology of atrioventricular block\", section on 'Medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long QT syndrome or torsades de pointes due to reversible causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     CONCURRENT ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who have a permanent pacemaker require an upgrade to an implantable cardioverter-defibrillator (ICD). Current ICDs have antitachycardia and antibradycardia pacing options. With very rare exceptions, patients now have only one device. Thus, in patients who have a permanent pacemaker and require an ICD, the pacemaker should be \"upgraded\" to an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H22#H22\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Additional capabilities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"       \"Patient information: Pacemakers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"       \"Patient information: Pacemakers (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7839495\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two general factors guide the vast majority of decisions regarding permanent pacemaker insertion: the association of symptoms with an arrhythmia and the potential for progression of the rhythm disturbance, which is largely dependent on the anatomical location of the conduction abnormality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients frequently present for consideration of pacemaker placement because of symptoms that may be due to bradyarrhythmias (eg, dizziness, lightheadedness, syncope, fatigue, and poor exercise tolerance). It is critical to attempt to establish a direct correlation between symptoms and bradyarrhythmias, which will increase the likelihood of recommending pacemaker placement. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The location of an atrioventricular (AV) conduction abnormality (ie, within the AV node or below the AV node in the His-Purkinje system) is an important determinant of both the probability and the likely pace of progression of conduction system disease. Disease below the AV node, in the His-Purkinje system, is generally considered to be less stable; as a result, permanent pacemaker placement is more likely to be recommended. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Location of conduction abnormality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common indications for pacemaker implantation are sinus node dysfunction followed by AV block. All other indications are much less common and include neurocardiogenic syncope and iatrogenic causes. (eg, post-AV node ablation). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Common indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conditions with a lack of adequate evidence of benefit from permanent pacing, in which permanent pacing is generally non indicated, include, among others, syncope of undetermined etiology, asymptomatic sinus bradycardia, asymptomatic first-degree and second-degree Mobitz I (Wenckebach) AV block, reversible AV block, and long QT syndrome or torsades de pointes due to a reversible cause. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Class III: Pacing not indicated'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/1\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/2\">",
"      Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation 2012; 126:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/3\">",
"      Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace 2007; 9:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/4\">",
"      Birnie D, Williams K, Guo A, et al. Reasons for escalating pacemaker implants. Am J Cardiol 2006; 98:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/5\">",
"      Hayes DL, Barold SS, Camm AJ, Goldschlager NF. Evolving indications for permanent cardiac pacing: an appraisal of the 1998 American College of Cardiology/American Heart Association Guidelines. Am J Cardiol 1998; 82:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/6\">",
"      Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group. Br Heart J 1991; 66:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/7\">",
"      Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol 2004; 44:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/8\">",
"      Scheinman MM, Peters RW, Suav&eacute; MJ, et al. Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacing. Am J Cardiol 1982; 50:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/9\">",
"      Dhingra RC, Wyndham C, Bauernfeind R, et al. Significance of block distal to the His bundle induced by atrial pacing in patients with chronic bifascicular block. Circulation 1979; 60:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27463/abstract/10\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 941 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27463=[""].join("\n");
var outline_f26_52_27463=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7839495\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Location of conduction abnormality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMMON INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Class I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Class II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Drug-induced sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acquired AV block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Class I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Class II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Drug-induced AV block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Role of EP study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Post myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Class I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Class II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neurocardiogenic syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Class I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Class II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Congenital complete heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Bradycardia-induced ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CLASS III: PACING NOT INDICATED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      CONCURRENT ICD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7839495\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24396\" title=\"table 1A\">",
"      ACC AHA HRS sinus dys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/57/5019\" title=\"table 1B\">",
"      Pacing for SA node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/23/23933\" title=\"table 2\">",
"      ACC AHA HRS AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/4/27724\" title=\"table 3A\">",
"      ACC AHA HRS fascic block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/44/18123\" title=\"table 3B\">",
"      Pacing in multifascicular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/41/17052\" title=\"table 4\">",
"      ACC AHA HRS pacing acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/27/14780\" title=\"table 5\">",
"      ACC AHA HRS pacing syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/16/39179\" title=\"table 6\">",
"      ACC AHA HRS HCM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=related_link\">",
"      Arrhythmias following cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=related_link\">",
"      Course and treatment of chronic bifascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_52_27464="Fenoprofen: Drug information";
var content_f26_52_27464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenoprofen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/39/3702?source=see_link\">",
"    see \"Fenoprofen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nalfon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nalfon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis, osteoarthritis: Oral: 300-600 mg 3-4 times/day; maximum dose: 3.2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate pain: Oral: 200 mg every 4-6 hours as needed; maximum dose: 3.2 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2532857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended in patients with advanced renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nalfon&reg;: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088655.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088655.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush tablets. Swallow whole with a full glass of water. Take with food to minimize stomach upset.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of acute and chronic rheumatoid arthritis and osteoarthritis; relief of mild-to-moderate pain",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14306728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fenoprofen may be confused with flurbiprofen",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (5%), palpitation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9%), somnolence (9%), dizziness (7%), nervousness (6%), fatigue (2%), confusion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Itching (4%), rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (10%), nausea (8%), constipation (7%), vomiting (3%), abdominal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5%), tremor (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (5%), hearing decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (3%), nasopharyngitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alkaline phosphatase increased, alopecia, anaphylaxis, angioedema (angioneurotic edema), anemia, anorexia, anuria, aphthous ulcerations, aplastic anemia, AST increased, atrial fibrillation, azotemia, blood in stool, bruising, burning tongue, cholestatic hepatitis, cystitis, depression, diplopia, disorientation, dysuria, exfoliative dermatitis, ECG changes, fever, flatulence, gastritis, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer, hematuria, hemolytic anemia, hemorrhage, hypertension, insomnia, interstitial nephritis, jaundice, LDH increased, lymphadenopathy, malaise, mastodynia, nephrosis, oliguria, optic neuritis, pancreatitis, pancytopenia, peptic ulcer, pulmonary edema, purpura, renal failure, renal papillary necrosis, seizure, Stevens-Johnson syndrome, supraventricular tachycardia, tachycardia, taste perversion, thrombocytopenia, toxic epidermal necrolysis, trigeminal neuralgia, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fenoprofen, aspirin, or other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; significant renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F170440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Fenoprofen peak serum levels may be decreased if taken with food; total amount absorbed is not affected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5261479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies fenoprofen as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5261481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very low levels of fenoprofen are found in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F170431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nalfon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (90): $245.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fenoprofen Calcium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $206.99",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC, liver enzymes; monitor urine output and BUN/serum creatinine in patients receiving diuretics; monitor blood pressure in patients receiving antihypertensives; audiogram (in patients with baseline hearing impairment)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F170423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 20-65 mcg/mL (SI: 82-268 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      FeiLin (CL);",
"     </li>",
"     <li>",
"      Fenopron (GB, HK, IE, KP);",
"     </li>",
"     <li>",
"      Fepron (TW);",
"     </li>",
"     <li>",
"      Nalfon (AT, BB, BM, BS, BZ, GY, JM, MX, NL, RU, SR, TT);",
"     </li>",
"     <li>",
"      Nalgesic (FR);",
"     </li>",
"     <li>",
"      Noprofen (TW);",
"     </li>",
"     <li>",
"      Progesic (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: A few days; full benefit: up to 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid, 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%; to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: &sim;2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (2% to 5% as unchanged drug); feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al. \"Pharmacodynamic Interaction Of Naproxen With Low-dose Aspirin In Healthy Subjects,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45 (8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al. \"Cyclooxygenase Inhibitors And The Antiplatelet Effects Of Aspirin,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):675-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/2642452/pubmed\" id=\"2642452\" target=\"_blank\">",
"        2642452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holland S, Silberstein SD, Freitag F, et al, &ldquo;Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1346-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/22529203/pubmed\" id=\"22529203\" target=\"_blank\">",
"        22529203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf. Accessed August 2, 2003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knodel LC, &ldquo;Preventing NSAID-Induced Ulcers: The Role of Misoprostol,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1989, 4:37-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pounder R, &ldquo;Silent Peptic Ulceration: Deadly Silence or Golden Silence?&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/2642448/pubmed\" id=\"2642448\" target=\"_blank\">",
"        2642448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stotts JS, Fang ML, Dannaker CJ, et al, &ldquo;Fenoprofen-Induced Toxic Epidermal Necrolysis,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1988, 18(4 Pt 1):755-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/3372773/pubmed\" id=\"3372773\" target=\"_blank\">",
"        3372773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/52/27464/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8440 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27464=[""].join("\n");
var outline_f26_52_27464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708779\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170444\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170445\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170471\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170448\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170449\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2532857\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881415\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170422\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170407\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874688\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803130\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170426\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14306728\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170479\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170469\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170429\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170411\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299317\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170416\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170440\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170418\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5261479\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170453\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5261481\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170431\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524572\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170420\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170423\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170432\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170410\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170428\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8440|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/39/3702?source=related_link\">",
"      Fenoprofen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_52_27465="Connection between osteocytes and blood vessels";
var content_f26_52_27465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Connection between osteocytes and blood vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The connection between osteocytes and blood vessels.",
"    <br>",
"     (A) Low (upper panel) and high (lower panel) magnifications of electron microscopy images demonstrating reliefs of the osteocytes and their canalicular network following acid-etching of murine bone sections (Courtesy of Lynda Bonewald from the University of Missouri and Kansas City Dental School). Please note multiple attachments of the osteocyte processes to the vessels depicted in the center of these images.",
"     <br>",
"      (B) Cartoon depicting the same connections.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Manolagas SC. From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266. Copyright &copy; 2010 The Endocrine Society.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27465=[""].join("\n");
var outline_f26_52_27465=null;
var title_f26_52_27466="Stress echocardiography in the diagnosis and prognosis of coronary heart disease";
var content_f26_52_27466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27466/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27466/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27466/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27466/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27466/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/52/27466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/52/27466/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/52/27466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress (exercise or pharmacologic) two-dimensional (2D) transthoracic echocardiography can be used to demonstrate the presence of coronary disease (by showing inducible wall motion abnormalities), to assess myocardial viability prior to revascularization, to identify a \"culprit\" lesion, to risk stratify patients with known or suspected disease, and for preoperative risk stratification prior to noncardiac surgery.",
"   </p>",
"   <p>",
"    The role of stress echocardiography in the diagnosis and prognosis of coronary heart disease (CHD) will be reviewed here.",
"   </p>",
"   <p>",
"    The techniques available for performing stress echocardiography and their safety, general discussions on the use of stress testing for the diagnosis and prognosis of known or suspected CHD, including acute coronary syndromes, and the advantages and limitations of the different stress tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=see_link\">",
"     \"Stress echocardiography: Indications, imaging techniques and safety\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=see_link\">",
"     \"Protocols for stress echocardiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRESS TEST OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice among the different types of stress tests is based upon the patient's ability to perform the exercise protocol, the possible presence of baseline electrocardiographic abnormalities that could interfere with the interpretation of the exercise electrocardiogram (ECG), and whether or not it is important to localize ischemia or assess myocardial viability (",
"    <a class=\"graphic graphic_algorithm graphicRef71324 \" href=\"UTD.htm?26/52/27470\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef58852 \" href=\"UTD.htm?23/60/24512\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Comparison of test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have reviewed the published literature comparing exercise ECG testing, stress echocardiography, and stress radionuclide myocardial perfusion imaging (rMPI) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The results with the different tests have generally been comparable, although some differences have been noted.",
"   </p>",
"   <p>",
"    The high specificity of stress echocardiography compared to other modalities contributes to its utility as a cost-effective diagnostic method [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/4\">",
"     4",
"    </a>",
"    ]. Evidence for the high specificity of stress echocardiography includes the results of two meta-analyses.",
"   </p>",
"   <p>",
"    One meta-analysis compared the performance of the following tests in patients with an intermediate pretest risk of CHD (25 to 75 percent): exercise ECG testing, planar thallium radionuclide myocardial perfusion imaging (rMPI), single photon emission computed tomography (SPECT) rMPI, stress echocardiography, and positron emission tomography (PET); all patients underwent coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/1\">",
"     1",
"    </a>",
"    ]. The extent of stenosis on angiography for the definition of significant CHD was usually defined &ge;50 or &ge;70 percent.",
"   </p>",
"   <p>",
"    The following values for sensitivity and specificity were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise ECG testing &mdash; 68 and 77 percent in 132 studies of over 24,000 patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link&amp;anchor=H4#H4\">",
"       \"Performance of exercise ECG testing\", section on 'Test accuracy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Planar thallium rMPI &mdash; 79 and 73 percent in six studies of 510 patients.",
"     </li>",
"     <li>",
"      SPECT rMPI &mdash; 88 and 77 percent in 10 studies of 1174 patients.",
"     </li>",
"     <li>",
"      Stress echocardiography &mdash; 76 and 88 percent in six studies of 510 patients.",
"     </li>",
"     <li>",
"      PET scanning &mdash; 91 and 82 percent in three studies of 206 patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second meta-analysis comparing exercise echocardiography and exercise SPECT rMPI for the diagnosis of CHD, 44 articles met criteria for determining sensitivity and specificity compared to coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/2\">",
"     2",
"    </a>",
"    ]. The extent of stenosis on angiography for the definition of significant CHD was variably defined &ge;50 to 75 percent. The two tests had similar sensitivity (85 and 87 percent), but the specificity was significantly higher (ie, fewer false positives) with exercise echocardiography (77 versus 64 percent).",
"   </p>",
"   <p>",
"    A number of studies have compared simultaneous stress echocardiography and stress rMPI. Stress echocardiography and stress rMPI (either both exercise or both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ) had similar overall accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Exercise echocardiography and exercise rMPI had comparable prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative accuracy of stress echocardiography and stress rMPI may be influenced by certain patient characteristics. As examples, stress echocardiography appears to be more accurate than stress rMPI in patients with left ventricular hypertrophy, while vasodilator stress rMPI may be superior in patients with high body mass index.",
"   </p>",
"   <p>",
"    A separate issue is the relative performance of the different agents used in pharmacologic stress echocardiography for the diagnosis of CHD. This problem was addressed in a 2001 regression meta-analysis of 82 studies involving 10,817 patients with angiographic data who underwent echocardiography or SPECT rMPI using adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/3\">",
"     3",
"    </a>",
"    ]. Dipyridamole and adenosine rMPI had the highest sensitivity (89 and 90 percent), dipyridamole echocardiography had the highest specificity (93 percent), and dobutamine echocardiography had the highest combination of sensitivity and specificity (80 and 84 percent, respectively) (",
"    <a class=\"graphic graphic_table graphicRef70485 \" href=\"UTD.htm?27/3/27707\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Prediction of event-free survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above observations evaluated the test performance of stress testing compared to coronary angiography. A separate issue is stress testing as a predictor of event-free survival.",
"   </p>",
"   <p>",
"    Among patients with known or suspected CHD, the negative predictive value of the test is important since a negative test may end the need for further diagnostic testing and allow the physician to reassure the patient of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    low risk for a cardiovascular event in the near future.",
"   </p>",
"   <p>",
"    In a meta-analysis of studies that evaluated event-free survival following exercise stress imaging with either rMPI or echocardiography in patients with known or suspected CHD, the negative predictive value for MI and cardiac death was 99 and 98 percent, respectively, over about three years in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most serious potential hindrance to the accuracy of stress echocardiography is that the images are subjectively interpreted with an accuracy that is dependent upon physician experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/11\">",
"     11",
"    </a>",
"    ], while radionuclide myocardial perfusion imaging lends itself well to semi-automated computer quantification, increasing both accuracy and reproducibility. However, interobserver variability for interpretation of stress echocardiography is low in experienced laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stress echocardiography has an advantage compared to stress rMPI since it provides information regarding left ventricular mass and valvular function. In an analysis of 1223 stress echocardiograms performed at one institution over a one-year period, an important Doppler abnormality was detected in 214 (17 percent), including at least moderate mitral regurgitation in 67 (5.5 percent) and at least mild aortic regurgitation in 163 (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several other advantages of stress echocardiography over stress rMPI, including lower cost, shorter patient time commitment, and avoidance of radiation exposure. The latter is an important issue to consider as patients often have multiple stress imaging tests during their lifetime.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Summary and ACC/AHA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the sensitivity of exercise ECG testing is lower than that of stress imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite this limitation, exercise ECG testing remains widely used in patients who can exercise to a level high enough to produce meaningful results and do not have ECG abnormalities that might interfere with interpretation because of two characteristics: lower cost; and, with use of a risk score such as the Duke treadmill score, the ability to identify patients (particularly men) at low and high clinical risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a stress imaging test is performed, the choice between echocardiography and rMPI should be based upon both local availability and local expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. In patients who can attain an adequate level of exercise (defined as &ge;85 of their predicted maximal heart rate), symptom-limited treadmill or bicycle exercise is the preferred form of stress because it provides the most information concerning patient symptoms, exercise capacity, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H5#H5\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Advantages of exercise stress'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2002 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    Task Force on chronic stable angina published recommendations for the use of stress imaging as the initial test for diagnosis or for risk assessment in patients who can or cannot exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/15\">",
"     15",
"    </a>",
"    ]; these guidelines were unchanged by the 2007 update [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/17\">",
"     17",
"    </a>",
"    ]. When used for diagnosis, stress testing is primarily of value in patients with an intermediate pretest probability (variably defined as between 25 and 75 percent or between 10 and 90 percent) (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines concluded that there was evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general agreement (class I) that stress echocardiography might be used as the initial test for diagnosis or risk stratification in patients with known or suspected CHD in a variety of settings.",
"   </p>",
"   <p>",
"    Among patients who are able to exercise:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise radionuclide myocardial perfusion imaging (rMPI) or exercise echocardiography to identify the extent, severity, and location of ischemia in patients with an intermediate pretest probability of disease who do not have left bundle branch block or a paced ventricular rhythm but have other resting ECG abnormalities that could interfere with the interpretation of exercise ECG testing (eg, preexcitation syndrome or more than 1 mm ST depression at rest).",
"     </li>",
"     <li>",
"      When used for diagnosis, exercise echocardiography or exercise rMPI in patients with prior revascularization; when used for prognosis, exercise echocardiography or exercise rMPI to assess the functional significance of coronary lesions, if not already known, prior to percutaneous coronary intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    perioperative guidelines regarding stress testing in patients with left bundle branch block concluded that exercise imaging (with either echocardiography or rMPI) was suboptimal (due to low specificity) and that either vasodilator rMPI or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography is preferred for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who are unable to exercise:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      echocardiography or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      or adenosine rMPI for diagnosis in patients with an intermediate pretest probability of CHD and, for prognosis, to identify the extent, severity, and location of ischemia.",
"     </li>",
"     <li>",
"      When used for diagnosis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      or adenosine rMPI in patients with prior revascularization; when used for prognosis, dobutamine echocardiography or dipyridamole or adenosine rMPI to assess the functional significance of coronary lesions, if not already known, prior to percutaneous coronary intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXERCISE ECHOCARDIOGRAPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use for diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise echocardiography or exercise rMPI is primarily recommended as the initial stress test in patients who can exercise but have baseline ECG abnormalities (eg, ST-T abnormalities) that interfere with interpretation of exercise ECG testing.",
"   </p>",
"   <p>",
"    In three reviews, exercise echocardiography (compared to coronary angiography) had a sensitivity of 79 to 85 percent and a specificity of 72 to 87 percent for the diagnosis of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/2,3,19\">",
"     2,3,19",
"    </a>",
"    ]. False negative results are more likely with submaximal exercise, single vessel disease, and moderate (50 to 70 percent) stenoses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, stress test accuracy is generally lower in women due in part to a lower prevalence of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Exercise level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo exercise ECG testing, a diagnostic test that fails to achieve at least 85 percent of the patient's predicted maximal heart rate is considered inadequate to exclude ischemic heart disease if the test is otherwise negative (ie, absence of chest discomfort or ECG findings) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An inadequate level of exercise is also a major cause of false negative exercise echocardiography studies. In a review of 114 patients with significant coronary stenoses at angiography, the sensitivity was 84 percent overall but increased to 90 percent when seven patients with submaximal exercise and a negative test were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, patients undergoing stress echocardiography for diagnosis should usually withhold antianginal medication prior to the test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link&amp;anchor=H25#H25\">",
"     \"Performance of exercise ECG testing\", section on 'Test endpoints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=see_link&amp;anchor=H9#H9\">",
"     \"Protocols for stress echocardiography\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Impact of timing of image acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main echocardiographic variable evaluated after or during exercise is the extent and severity of exercise-induced left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When treadmill exercise stress is used, images are obtained immediately after exercise since imaging during exercise is not feasible. A potential problem with this approach is that ischemia may resolve rapidly after discontinuing the exercise and a wall motion abnormality that developed during peak exercise may rapidly reverse to normal after the test is stopped. Thus, images need to be acquired as rapidly as possible (within 60 to 90 seconds after cessation of exercise).",
"   </p>",
"   <p>",
"    Although a report suggested that imaging during rather than after treadmill stress may be feasible and yield greater sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/25\">",
"     25",
"    </a>",
"    ], the efficacy of this approach has not been confirmed by others.",
"   </p>",
"   <p>",
"    When exercise echocardiography is performed during supine or upright bicycle exercise, images are obtained during exercise so ischemic dysfunction is more likely to be captured if adequate workloads are attained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=see_link\">",
"     \"Protocols for stress echocardiography\"",
"    </a>",
"    .) Continuous echocardiographic monitoring has another potential advantage in that it permits detection of the \"biphasic response\" of dysfunctional yet viable myocardium that is characterized by initial improvement of regional function followed by deterioration. This is similar to the biphasic response detected during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Akinetic segments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The possible value of this approach was illustrated in a report of 114 patients with a recent MI (within one week) and at least two dyssynergic segments in whom exercise testing was performed in a semi-supine position on a tilting exercise table, permitting continuous echocardiographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/26\">",
"     26",
"    </a>",
"    ]. Residual ischemia was identified in 77 patients (biphasic response in 62, progressive worsening of function in 15). Quantitative coronary angiography was then performed: the biphasic response to exercise was more sensitive in predicting a significant infarct-related artery stenosis than the progressive worsening response (61 versus 14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Use for prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both exercise variables and echocardiographic findings contribute to the prognostic value of exercise echocardiography. As with any modality of exercise testing, bad prognostic signs include poor exercise capacity (&lt;5 metabolic equivalents [METs]); exercise-induced angina; abnormally low peak systolic blood pressure (&lt;130 mmHg) or a fall in the systolic blood pressure during exercise; and chronotropic incompetence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/22,27,28\">",
"     22,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H2#H2\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Adverse predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main prognostic echocardiographic variable is the extent and severity of exercise-induced left ventricular dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef68442 \" href=\"UTD.htm?4/62/5102\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Although cardiac events occur more often in men, exercise echocardiography provides incremental prognostic value in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/22,29,30\">",
"     22,29,30",
"    </a>",
"    ]. Incremental prognostic value has also been demonstrated in patients &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/31\">",
"     31",
"    </a>",
"    ], in patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/32\">",
"     32",
"    </a>",
"    ], and after coronary artery bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A normal exercise echocardiogram identifies patients at low short-term cardiac risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/9,23,27\">",
"     9,23,27",
"    </a>",
"    ]. This was illustrated in a report of 1325 patients who were followed after a normal study; the one and three-year cardiac event-free survival rates were 99 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/27\">",
"     27",
"    </a>",
"    ]. Independent predictors of subsequent cardiac events included exercise-induced angina, low workload (both of which are also predictive with exercise ECG testing), and echocardiographic left ventricular hypertrophy.",
"   </p>",
"   <p>",
"    Similar findings were noted in a meta-analysis cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/9\">",
"     9",
"    </a>",
"    ]. Event-free survival after a negative exercise echocardiography study in patients with known or suspected CHD was 98 percent at 33 months, with MI or cardiac death of only 0.54 percent per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     With other exercise data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of exercise echocardiography is enhanced by combining echocardiographic findings with other exercise test data. The combined utility of exercise echocardiography and the Duke treadmill score was evaluated in a study of 5375 patients with known or suspected CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At a mean follow-up of 5.5 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a low risk Duke treadmill score, the yearly mortality in those with a normal rest echo study or evidence of disease in a single or multivessel territory was 0.7, 1.8, and 3 percent, respectively. Although multivessel territory disease on echocardiography was associated with increased risk, it was present in only 1.4 percent of patients with a low risk Duke treadmill score.",
"     </li>",
"     <li>",
"      Among patients with a moderate risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 2.4, 3.7, and 7 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a high risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 4.6, 5, and 12 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a normal echocardiographic study, the yearly mortality was 1 percent overall, and 0.7, 2.4, and 4.6 percent, respectively, in patients with a low, moderate, and high risk Duke treadmill score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overall cardiac event rate &le;1 percent per year with a normal test has also been noted in other studies of patients undergoing exercise echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/27\">",
"     27",
"    </a>",
"    ] and in patients with normal findings on pharmacologic stress echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/34\">",
"     34",
"    </a>",
"    ] or stress radionuclide myocardial perfusion imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise echocardiography adds incremental prognostic value to good exercise capacity, which generally predicts a favorable outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/24,38\">",
"     24,38",
"    </a>",
"    ]. This was illustrated in a study of 1874 patients with known or suspected coronary artery disease, an exercise capacity of &ge;5 METs in women and &ge;7 METS in men, and an abnormal exercise echocardiogram (rest or exercise regional wall motion abnormalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/24\">",
"     24",
"    </a>",
"    ]. The cardiac event rate (cardiac death or nonfatal MI) was 1.2, 2.2, and 3.8 percent per year of follow-up for 0, 1 to 25, and &gt;25 percent of left ventricular segments that were severely abnormal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognostic value of exercise echocardiography in patients with normal exercise ECG testing was demonstrated in a study of 4004 patients with interpretable ECGs who underwent stress treadmill echocardiography with no chest pain or ischemic ECG changes during the test [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/38\">",
"     38",
"    </a>",
"    ]. Stress imaging was performed while the patient was walking (a less common approach); (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=see_link&amp;anchor=H4#H4\">",
"     \"Protocols for stress echocardiography\", section on 'Treadmill'",
"    </a>",
"    ). Ischemia (defined as new or worsening wall motion abnormalities during exercise) was observed in 17 percent of patients. Follow-up for mortality and major cardiac events was performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five-year mortality and major cardiac event rates were 6 and 4 percent in patients without ischemia and 12 and 10 percent in those with ischemia.",
"     </li>",
"     <li>",
"      Multivariate predictors of mortality and major cardiac events included male sex, stress-induced wall motion abnormalities, and resting wall motion abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Special settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of exercise echocardiography may be affected by the presence of left bundle branch block, a significant hypertensive response to exercise or a prior MI. It does not appear to be influenced by the presence of left ventricular hypertrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Left bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the use of exercise echocardiography in patients with left bundle branch block (LBBB). As noted above, the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    perioperative guidelines concluded that the accuracy of exercise imaging (either echocardiography or rMPI) is suboptimal in patients with LBBB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/18\">",
"     18",
"    </a>",
"    ]. Pharmacologic stress testing with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography or vasodilator rMPI is recommended for these patients. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Summary and ACC/AHA guidelines'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy may interfere with the reliability of exercise ECG testing, particularly if more than 1 mm of ST segment depression is present at rest (",
"    <a class=\"graphic graphic_table graphicRef52995 graphicRef74428 \" href=\"UTD.htm?14/46/15086\">",
"     table 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/15\">",
"     15",
"    </a>",
"    ]. Exercise echocardiography appears to be preferable to exercise or pharmacologic stress rMPI in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/5,39\">",
"     5,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic accuracy of exercise echocardiography was illustrated in a report of 68 patients with echocardiographic evidence of left ventricular hypertrophy who underwent exercise echocardiography and coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/40\">",
"     40",
"    </a>",
"    ]. The sensitivity, specificity, and diagnostic accuracy of exercise echocardiography were 71, 95, and 85 percent, respectively, for the diagnosis of coronary artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hypertensive response to exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive exercise echocardiography tests are more common in patients with an excessive increase in blood pressure during exercise. This was illustrated in a series of 132 patients who had a hypertensive response to exercise (systolic blood pressure &gt;220 mmHg for men or &gt;190 mmHg for women or diastolic blood pressure &gt;90 mmHg or an increase &gt;10 mmHg): a false positive test (ie, echocardiogram positive for ischemia in the absence of significant coronary artery disease on angiography) occurred in 22 percent of these compared to 12 percent of 320 patients without a hypertensive response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/41\">",
"     41",
"    </a>",
"    ]. False positive results were significantly more extensive in the patients with a hypertensive response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2998?source=see_link&amp;anchor=H5#H5\">",
"     \"Exercise in the treatment and prevention of hypertension\", section on 'Exaggerated exercise-induced hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of exercise echocardiography in patients with a prior MI was addressed in a study of 347 patients with and without a prior MI who underwent exercise echocardiography and coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/42\">",
"     42",
"    </a>",
"    ]. Although overall sensitivity was higher in those with a prior MI (95 versus 82 percent without an MI), the overall specificity was much lower (44 versus 84 percent). The sensitivity and specificity for detecting a residual stenosis in the infarct-related artery was 91 and 59 percent, respectively; specificity was better when the MI was small (86 versus 33 percent for large MI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DOBUTAMINE STRESS ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography has become increasingly popular, especially for patients who cannot complete a physiologic (ie, exercise) stress test. In contrast to radionuclide myocardial perfusion imaging and exercise echocardiography, images are obtained at increasing levels of stress and during peak stress. This technique is based upon the premise that the contractile function of myocardial regions perfused by arteries with significant stenoses will be impaired when regional ischemia is provoked by the inotropic and chronotropic effects of dobutamine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    increases heart rate and myocardial contractility. The onset of action is within one to two minutes of intravenous infusion, the half-life is two minutes, and the drug is metabolized via methylation and conjugation. At a dose of 20",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min, there is a small but significant increase in systolic blood pressure (mean 12 mmHg in one report) and at 40",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min, the mean heart rate is 120 to 125",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef56035 \" href=\"UTD.htm?7/10/7342\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress transesophageal echocardiography is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Addition of atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    should be added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    when the maximum predicted heart rate for age is not achieved at the peak dose of dobutamine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/4\">",
"     4",
"    </a>",
"    ]. The combination of dobutamine and atropine produces hyperemia, with a more than fivefold increase in myocardial blood flow compared to baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One reason for failure to achieve the maximum predicted heart rate is competitive antagonism of the physiologic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    by beta blocker therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. This masking effect of beta blockers is due to reductions in the heart rate response and the rate of rise in left ventricular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of patients undergoing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography, 26 percent were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    because they did not achieve the target heart rate, often because of beta blocker therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/49\">",
"     49",
"    </a>",
"    ]. The addition of 0.5 to 2.0 mg of atropine enhances the ability of dobutamine to induce ischemia in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography was evaluated in a study of 1171 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/49\">",
"     49",
"    </a>",
"    ]. Stress-induced ischemia developed in 444 patients, 70 (16 percent) of whom required atropine before ischemia became evident; many of these patients had single vessel disease and presumably had a higher ischemic threshold. Atropine increased the sensitivity from 90 to 95 percent overall, and from 65 to 84 percent in patients with normal wall motion at rest.",
"   </p>",
"   <p>",
"    If the target heart rate, defined as 85 percent of the age-predicted maximum heart rate, is not achieved with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , prognosis after a normal test is not necessarily benign [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Use for diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography is importantly dependent upon the degree of stenosis, the amount of myocardium at risk, and the degree of deterioration in wall motion as illustrated by the following observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 75 patients with normal left ventricular systolic function, the degree of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      -induced wall motion dyssynergy correlated significantly with percent diameter stenosis (r = 0.68) and inversely with minimal luminal diameter (r = -0.60) and myocardial fractional flow reserve (r = -0.77) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/53\">",
"       53",
"      </a>",
"      ]. In patients with a functionally significant stenosis, the amount of myocardium at risk was an important determinant of accuracy.",
"     </li>",
"     <li>",
"      The extent of myocardium at risk was also important in a series of 283 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/53\">",
"       53",
"      </a>",
"      ]. The positive predictive value increased with the number of segments in which wall motion deteriorated and with the severity of wall motion deterioration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reports from multiple centers have demonstrated good sensitivity and specificity with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography for the diagnosis of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/1,3,43,44,54,55\">",
"     1,3,43,44,54,55",
"    </a>",
"    ]. A review of 28 published studies involving 2246 patients reported an overall sensitivity, specificity, and accuracy of 80, 84, and 81 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/55\">",
"     55",
"    </a>",
"    ]. The sensitivity was related to the number of diseased vessels, being 74, 86, and 92 percent for one, two, and three vessel disease, respectively.",
"   </p>",
"   <p>",
"    Similar findings were noted in a regression meta-analysis of 82 studies involving 10,817 patients with angiographic data who underwent echocardiography or single photon emission computed tomography (SPECT) radionuclide myocardial perfusion imaging (rMPI) using adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/3\">",
"     3",
"    </a>",
"    ]. Dobutamine echocardiography had the highest combination of sensitivity and specificity (80 and 84 percent, respectively), while dipyridamole and adenosine rMPI had the highest sensitivity (89 and 90 percent) and dipyridamole echocardiography had the highest specificity (93 percent) (",
"    <a class=\"graphic graphic_table graphicRef70485 \" href=\"UTD.htm?27/3/27707\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a small study, real time, three-dimensional (RT-3D) echocardiography was compared to conventional 2D echocardiography during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress in 36 patients with suspected coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/56\">",
"     56",
"    </a>",
"    ]. Using coronary arteriography as the standard, RT-3D and 2D echocardiography had similar sensitivity, specificity, and number of evaluable cases (93, 75 and 98 percent, respectively). Imaging acquisition time was significantly shorter with RT-3D (55 versus 137 seconds with 2D echocardiography). The imaging acquisition time for 2D echocardiography was relatively prolonged in this study and the clinical utility of RT-3D stress echocardiography remains to be defined by larger multicenter trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=see_link&amp;anchor=H2#H2\">",
"     \"Three-dimensional echocardiography\", section on 'Clinical applications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography may be of particular value for evaluating patients with hypertension who have chest pain. In these patients, exercise ECG testing is not a reliable predictor of epicardial coronary artery disease since ST segment changes consistent with ischemia (often due to left ventricular hypertrophy) can occur without significant coronary disease on angiography. In some, but not all studies, radionuclide perfusion imaging is also suboptimal.",
"   </p>",
"   <p>",
"    Test choice in hypertensive patients was addressed in a study in which",
"    <span class=\"nowrap\">",
"     stress/rest",
"    </span>",
"    sestamibi rMPI, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stress echocardiography, and coronary angiography were performed in 101 patients with hypertension, chest pain, and a positive exercise ECG test; 56 percent had significant CHD and a similar proportion had left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/57\">",
"     57",
"    </a>",
"    ]. Dobutamine stress echocardiography had a sensitivity and specificity of 88 and 80 percent, respectively, and there was a trend toward greater accuracy than with dipyridamole echocardiography (84 versus 74 percent). Dobutamine stress echocardiography had a higher specificity (80 versus 36 percent) and positive predictive value (85 versus 67 percent) than rMPI. The low specificity of perfusion imaging was probably related to the detection of perfusion abnormalities that were not caused by CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Variant angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    provokes vasospasm in some patients with variant angina. This was demonstrated in a report of 51 patients with documented variant angina, seven (14 percent) of whom had a positive dobutamine echocardiogram associated with chest discomfort and ST segment elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Akinetic segments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment is different in segments that are initially akinetic. For these myocardial regions, ischemia (as detected by concurrent thallium imaging) correlates with improved motion with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    (5 to 10",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min) followed by worsening with higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/59\">",
"     59",
"    </a>",
"    ]. When this occurs, the diagnostic accuracy is equivalent with mild, moderate, or severe wall motion abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar biphasic response in abnormal but not akinetic segments may indicate hibernating myocardium. The initial improvement in wall motion reflects recruitment of contractile reserve during low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . In comparison, higher doses lead to subendocardial ischemia and worsening of the wall motion abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Use for prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography provides prognostic information concerning possible future cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/5,12,34,61-68\">",
"     5,12,34,61-68",
"    </a>",
"    ]. As with exercise echocardiography, the prognosis varies with the presence, severity, and extent of the induced ischemia. The prognostic value applies to women as well as men [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential prognostic value of stress echocardiography was illustrated in studies from the Echo-Persantine International Cooperative-Echo-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    International Cooperative data bank [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/34,61,62\">",
"     34,61,62",
"    </a>",
"    ]. In a review of 7333 consecutive patients referred for known or suspected CHD, pharmacologic stress echocardiography was performed using either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or dobutamine; the test was positive in 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/34\">",
"     34",
"    </a>",
"    ]. Kaplan-Meier survival estimates were significantly lower in those with a positive test (71 versus 92 percent), with an estimated mortality of less than 1 percent per year in patients with a negative test. The predictive value was additive to clinical variables and resting echocardiographic wall motion abnormalities.",
"   </p>",
"   <p>",
"    Another report from the same group evaluated 754 patients with single vessel coronary disease who underwent either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography; 56 percent had a positive study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/61\">",
"     61",
"    </a>",
"    ]. Three major findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among medically treated patients, the four year MI-free survival rate was significantly lower in those with a positive test (87 versus 94 percent); there was no significant difference in outcome according to test results among those treated invasively (",
"      <a class=\"graphic graphic_figure graphicRef74522 \" href=\"UTD.htm?22/57/23454\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among patients with a positive test, the four year MI-free survival rate was significantly higher with an invasive strategy compared to medical therapy (97 versus 87 percent); there was no difference in outcome according to therapy in those with a negative test.",
"     </li>",
"     <li>",
"      Among patients at low-to-moderate risk for a cardiac event,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      stress echocardiography had similar negative (83 versus 84 percent) and positive predictive values (17 and 19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis appears to vary with specific findings on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/12,34,63,65,69-71\">",
"     12,34,63,65,69-71",
"    </a>",
"    ]. Dobutamine stress echocardiography is predictive of events in patients with [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/70\">",
"     70",
"    </a>",
"    ] or without [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/71\">",
"     71",
"    </a>",
"    ] resting left ventricular systolic dysfunction.",
"   </p>",
"   <p>",
"    The prognostic value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography was illustrated by a report of 3156 patients who were followed for up to 9 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/63\">",
"     63",
"    </a>",
"    ]. The number of abnormal territories at peak stress and the type of wall motion abnormality (ischemia or scar as defined by wall motion abnormalities occurring only during exercise or being present at rest, respectively) were independent predictors of cardiac events (",
"    <a class=\"graphic graphic_figure graphicRef64154 graphicRef75910 \" href=\"UTD.htm?21/20/21824\">",
"     figure 4A-B",
"    </a>",
"    ). The adverse prognosis associated with resting wall motion abnormalities has also been noted in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography and dobutamine SPECT rMPI appear to have equivalent predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/5,68\">",
"     5,68",
"    </a>",
"    ]. This was demonstrated in a study of 301 patients who were unable to exercise and who underwent both dobutamine echocardiography and dobutamine SPECT rMPI; the tests were abnormal in 60 and 66 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/68\">",
"     68",
"    </a>",
"    ]. At a mean follow-up of seven years, there were 43 cardiac deaths (14 percent) and 121 patients with cardiac events (cardiac death, myocardial infarction, or coronary revascularization; 40 percent). The predictive results for dobutamine echocardiography and dobutamine SPECT rMPI were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a normal test, annual cardiac death rates were 0.6 and 0.7 percent and annual cardiac event rates were 3.3 and 3.6 percent",
"     </li>",
"     <li>",
"      With an abnormal test, annual cardiac death rates were 2.8 and 2.6 percent and annual cardiac event rates were 6.9 and 6.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     With other stress test data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic value of a positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiogram can also be enhanced by combining echocardiographic findings with other stress test data. As an example, the combined utility of assessing resting wall motion, the stress ECG response, and the dobutamine ejection fraction was evaluated in a report of 1183 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/67\">",
"     67",
"    </a>",
"    ]. The overall cardiac event rate at one year was significantly increased in patients with a positive test (34 versus 10 percent with a negative test) and in those with resting wall motion abnormality (25 versus 6 percent with no resting abnormality). When both the dobutamine echocardiogram and the dobutamine ECG were considered, the cardiac event rate at one year was much higher when both were positive for ischemia (42 versus 7 percent when both were negative).",
"   </p>",
"   <p>",
"    Another study developed a combined clinical, exercise, and echocardiographic score for predicting prognosis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/72\">",
"     72",
"    </a>",
"    ]. Data from a series of 1456 patients were used to develop a multivariate model for the prediction of the combined end point of cardiac death or myocardial infarction. The resulting prediction model was as follows:",
"   </p>",
"   <p>",
"    &nbsp;Risk score &nbsp;= &nbsp;(age &nbsp;x &nbsp;0.02) &nbsp;+ &nbsp;[(heart failure history &nbsp;+ &nbsp;rate-pressure product &lt;15,000) &nbsp;x &nbsp;0.4] &nbsp;+ &nbsp;[(ischemia &nbsp;+ &nbsp;scar) &nbsp;x &nbsp;0.6]",
"   </p>",
"   <p>",
"    In this calculation, heart failure history, rate-pressure product &lt;15,000, ischemia and scar are all scored 1 if present and 0 if absent; age is determined in years. The resulting values for risk are interpreted as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Risk score &lt;1.2 &mdash; low risk; &gt;97 percent five-year event-free survival",
"     </li>",
"     <li>",
"      Risk score 1.2 to 2.6 &mdash; intermediate risk; 75 to 97 percent five-year event-free survival",
"     </li>",
"     <li>",
"      Risk score &gt;2.6 &mdash; high risk; &lt;75 percent five-year event-free survival",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This risk score was validated in two additional cohorts of 1458 and 1733 patients, with comparable outcomes to those seen in the derivation cohort.",
"   </p>",
"   <p>",
"    A risk score including DSE variables has also been described in older adults with diabetes, but has not been prospectively validated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     With induced angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 2117 patients who did not have inducible wall motion abnormalities, 10 percent developed angina during the test [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/74\">",
"     74",
"    </a>",
"    ]. These patients compared to those without angina were more likely to have a history of exertional angina and had a significantly higher rate of revascularization during a mean follow-up of 5.3 years (39 versus 14 percent). However, there was no difference in death or nonfatal MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     With ST elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 4240 consecutive patients undergoing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography, 134 (3 percent) developed new stress-induced ST segment elevations &ge;1 mm in at least two contiguous ECG leads [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/75\">",
"     75",
"    </a>",
"    ]. All of these patients had an abnormal test, with ischemia occurring in 86 percent. Coronary angiography was performed in one-half of patients: &ge;70 percent diameter stenosis was present in all and involved multiple vessels in 77 percent. At 2.6 year follow-up, 40 percent died and event-free survival was only 55 percent at two years and 28 percent at five years. Thus, ST segment elevation during dobutamine echocardiography was a marker of severe disease and high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     With contrast echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography may be increased by concurrent performance of real-time contrast echocardiography to assess myocardial perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential value of this approach was illustrated in a retrospective study of 788 patients who underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress with injection of microbubbles for real-time contrast echocardiography; 75 patients (9.6 percent) died or had a nonfatal MI at a median follow-up of 20 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/76\">",
"     76",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of studies recognized as abnormal increased from 26 to 41 percent by the addition of contrast echocardiography. In addition, ischemia was recognized within some areas thought to have infarction.",
"     </li>",
"     <li>",
"      Abnormal myocardial perfusion added significant incremental predictive value to clinical factors, the resting left ventricular ejection fraction, and wall motion abnormalities.",
"     </li>",
"     <li>",
"      The three-year event-free survival was 95 percent in patients with normal wall motion and myocardial perfusion, 82 percent with normal wall motion and abnormal myocardial perfusion, and 68 percent for abnormalities in both wall motion and myocardial perfusion.",
"     </li>",
"     <li>",
"      Three-year event-free survival was significantly lower with multivessel perfusion defects (56 versus 85 percent with a single vessel perfusion defect).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Special settings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Left bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    perioperative guidelines concluded that the accuracy of exercise imaging (either echocardiography or rMPI) is suboptimal in patients with left bundle branch block (LBBB) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/18\">",
"     18",
"    </a>",
"    ]. Pharmacologic stress testing with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography or vasodilator rMPI is recommended for these patients. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Summary and ACC/AHA guidelines'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy may interfere with the reliability of exercise ECG testing, especially if more than 1 mm of ST segment depression is present at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/15\">",
"     15",
"    </a>",
"    ]. The sensitivity and specificity of stress rMPI may also be reduced in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/5,39\">",
"     5,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic stress echocardiography appears to retain diagnostic accuracy in most patients with left ventricular hypertrophy. This was illustrated in a study of 386 patients with left ventricular hypertrophy and known or suspected coronary disease who underwent both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    stress echocardiography and coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/77\">",
"     77",
"    </a>",
"    ]. The overall sensitivity, specificity, and diagnostic accuracy of stress echocardiography were 85, 87, and 86 percent, respectively, for the diagnosis of coronary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Paced ventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend pharmacologic stress MPI in patients with a paced ventricular rhythm (",
"    <a class=\"graphic graphic_table graphicRef52995 graphicRef74428 \" href=\"UTD.htm?14/46/15086\">",
"     table 3A-B",
"    </a>",
"    ). The potential value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography in this setting is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     VASODILATOR STRESS ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasodilators",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    and adenosine have been used as stressors for echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/34,50,61,62,78-81\">",
"     34,50,61,62,78-81",
"    </a>",
"    ]. However, vasodilator rMPI is preferred because vasodilator echocardiography is substantially less sensitive (",
"    <a class=\"graphic graphic_table graphicRef70485 \" href=\"UTD.htm?27/3/27707\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/3,82\">",
"     3,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither adenosine nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    echocardiography is widely used in the United States and neither was recommended for the diagnosis or risk stratification of CHD by the 2002 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    Task Force on chronic stable angina (",
"    <a class=\"graphic graphic_table graphicRef52995 graphicRef74428 \" href=\"UTD.htm?14/46/15086\">",
"     table 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/52/27466/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       \"Patient information: Echocardiogram (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/1\">",
"      Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999; 130:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/2\">",
"      Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/3\">",
"      Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis. Am Heart J 2001; 142:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/4\">",
"      Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/5\">",
"      Marwick T, D'Hondt AM, Baudhuin T, et al. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? J Am Coll Cardiol 1993; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/6\">",
"      Qui&ntilde;ones MA, Verani MS, Haichin RM, et al. Exercise echocardiography versus 201Tl single-photon emission computed tomography in evaluation of coronary artery disease. Analysis of 292 patients. Circulation 1992; 85:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/7\">",
"      Forster T, McNeill AJ, Salustri A, et al. Simultaneous dobutamine stress echocardiography and technetium-99m isonitrile single-photon emission computed tomography in patients with suspected coronary artery disease. J Am Coll Cardiol 1993; 21:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/8\">",
"      Mairesse GH, Marwick TH, Vanoverschelde JL, et al. How accurate is dobutamine stress electrocardiography for detection of coronary artery disease? Comparison with two-dimensional echocardiography and technetium-99m methoxyl isobutyl isonitrile (mibi) perfusion scintigraphy. J Am Coll Cardiol 1994; 24:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/9\">",
"      Metz LD, Beattie M, Hom R, et al. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. J Am Coll Cardiol 2007; 49:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/10\">",
"      Olmos LI, Dakik H, Gordon R, et al. Long-term prognostic value of exercise echocardiography compared with exercise 201Tl, ECG, and clinical variables in patients evaluated for coronary artery disease. Circulation 1998; 98:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/11\">",
"      Roger VL, Pellikka PA, Oh JK, et al. Stress echocardiography. Part I. Exercise echocardiography: techniques, implementation, clinical applications, and correlations. Mayo Clin Proc 1995; 70:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/12\">",
"      Chuah SC, Pellikka PA, Roger VL, et al. Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease. Circulation 1998; 97:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/13\">",
"      Gaur A, Yeon SB, Lewis CW, Manning WJ. Valvular flow abnormalities are often identified by a resting focused Doppler examination performed at the time of stress echocardiography. Am J Med 2003; 114:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/14\">",
"      Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001; 344:1840.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/16\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/17\">",
"      Fraker TD Jr, Fihn SD, 2002 Chronic Stable Angina Writing Committee, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/18\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/19\">",
"      de Albuquerque Fonseca L, Picano E. Comparison of dipyridamole and exercise stress echocardiography for detection of coronary artery disease (a meta-analysis). Am J Cardiol 2001; 87:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/20\">",
"      Marwick TH, Nemec JJ, Pashkow FJ, et al. Accuracy and limitations of exercise echocardiography in a routine clinical setting. J Am Coll Cardiol 1992; 19:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/21\">",
"      Hlatky MA, Pryor DB, Harrell FE Jr, et al. Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med 1984; 77:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/22\">",
"      Arruda-Olson AM, Juracan EM, Mahoney DW, et al. Prognostic value of exercise echocardiography in 5,798 patients: is there a gender difference? J Am Coll Cardiol 2002; 39:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/23\">",
"      Marwick TH, Case C, Vasey C, et al. Prediction of mortality by exercise echocardiography: a strategy for combination with the duke treadmill score. Circulation 2001; 103:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/24\">",
"      McCully RB, Roger VL, Mahoney DW, et al. Outcome after abnormal exercise echocardiography for patients with good exercise capacity: prognostic importance of the extent and severity of exercise-related left ventricular dysfunction. J Am Coll Cardiol 2002; 39:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/25\">",
"      Peteiro J, Garrido I, Monserrat L, et al. Comparison of peak and postexercise treadmill echocardiography with the use of continuous harmonic imaging acquisition. J Am Soc Echocardiogr 2004; 17:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/26\">",
"      Lancellotti P, Hoffer EP, Pi&eacute;rard LA. Detection and clinical usefulness of a biphasic response during exercise echocardiography early after myocardial infarction. J Am Coll Cardiol 2003; 41:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/27\">",
"      McCully RB, Roger VL, Mahoney DW, et al. Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients. J Am Coll Cardiol 1998; 31:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/28\">",
"      Lauer MS, Mehta R, Pashkow FJ, et al. Association of chronotropic incompetence with echocardiographic ischemia and prognosis. J Am Coll Cardiol 1998; 32:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/29\">",
"      Heupler S, Mehta R, Lobo A, et al. Prognostic implications of exercise echocardiography in women with known or suspected coronary artery disease. J Am Coll Cardiol 1997; 30:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/30\">",
"      Shaw LJ, Vasey C, Sawada S, et al. Impact of gender on risk stratification by exercise and dobutamine stress echocardiography: long-term mortality in 4234 women and 6898 men. Eur Heart J 2005; 26:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/31\">",
"      Arruda AM, Das MK, Roger VL, et al. Prognostic value of exercise echocardiography in 2,632 patients &gt; or = 65 years of age. J Am Coll Cardiol 2001; 37:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/32\">",
"      Elhendy A, Arruda AM, Mahoney DW, Pellikka PA. Prognostic stratification of diabetic patients by exercise echocardiography. J Am Coll Cardiol 2001; 37:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/33\">",
"      Arruda AM, McCully RB, Oh JK, et al. Prognostic value of exercise echocardiography in patients after coronary artery bypass surgery. Am J Cardiol 2001; 87:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/34\">",
"      Sicari R, Pasanisi E, Venneri L, et al. Stress echo results predict mortality: a large-scale multicenter prospective international study. J Am Coll Cardiol 2003; 41:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/35\">",
"      Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998; 97:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/36\">",
"      Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age. Circulation 1991; 83:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/37\">",
"      Poornima IG, Miller TD, Christian TF, et al. Utility of myocardial perfusion imaging in patients with low-risk treadmill scores. J Am Coll Cardiol 2004; 43:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/38\">",
"      Bouzas-Mosquera A, Peteiro J, Alvarez-Garc&iacute;a N, et al. Prediction of mortality and major cardiac events by exercise echocardiography in patients with normal exercise electrocardiographic testing. J Am Coll Cardiol 2009; 53:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/39\">",
"      Marwick TH, Cook SA, Lafont A, et al. Influence of left ventricular mass on the diagnostic accuracy of myocardial perfusion imaging using positron emission tomography with dipyridamole stress. J Nucl Med 1991; 32:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/40\">",
"      Marwick TH, Torelli J, Harjai K, et al. Influence of left ventricular hypertrophy on detection of coronary artery disease using exercise echocardiography. J Am Coll Cardiol 1995; 26:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/41\">",
"      Ha JW, Juracan EM, Mahoney DW, et al. Hypertensive response to exercise: a potential cause for new wall motion abnormality in the absence of coronary artery disease. J Am Coll Cardiol 2002; 39:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/42\">",
"      Nishioka T, Mitani H, Uehata A, et al. Utility and limitation of treadmill exercise echocardiography for detecting significant coronary stenosis in infarct-related arteries in patients with healed myocardial infarction. Am J Cardiol 2002; 89:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/43\">",
"      Verani MS. Pharmacologic stress myocardial perfusion imaging. Curr Probl Cardiol 1993; 18:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/44\">",
"      Iskandrian AS, Verani MS, Heo J. Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. J Nucl Cardiol 1994; 1:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/45\">",
"      Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing. J Am Coll Cardiol 1993; 21:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/46\">",
"      Tadamura E, Iida H, Matsumoto K, et al. Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men. J Am Coll Cardiol 2001; 37:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/47\">",
"      Shehata AR, Gillam LD, Mascitelli VA, et al. Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. Am J Cardiol 1997; 80:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/48\">",
"      Chen L, Ma L, de Prada VA, et al. Effects of beta-blockade and atropine on ischemic responses in left ventricular regions subtending coronary stenosis during dobutamine stress echocardiography. J Am Coll Cardiol 1996; 28:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/49\">",
"      Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996; 28:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/50\">",
"      Pingitore A, Picano E, Colosso MQ, et al. The atropine factor in pharmacologic stress echocardiography. Echo Persantine (EPIC) and Echo Dobutamine International Cooperative (EDIC) Study Groups. J Am Coll Cardiol 1996; 27:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/51\">",
"      Fioretti PM, Poldermans D, Salustri A, et al. Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers. Eur Heart J 1994; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/52\">",
"      Chaowalit N, McCully RB, Callahan MJ, et al. Outcomes after normal dobutamine stress echocardiography and predictors of adverse events: long-term follow-up of 3014 patients. Eur Heart J 2006; 27:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/53\">",
"      Bartunek J, Marwick TH, Rodrigues AC, et al. Dobutamine-induced wall motion abnormalities: correlations with myocardial fractional flow reserve and quantitative coronary angiography. J Am Coll Cardiol 1996; 27:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/54\">",
"      Rallidis L, Cokkinos P, Tousoulis D, Nihoyannopoulos P. Comparison of dobutamine and treadmill exercise echocardiography in inducing ischemia in patients with coronary artery disease. J Am Coll Cardiol 1997; 30:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/55\">",
"      Geleijnse ML, Fioretti PM, Roelandt JR. Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol 1997; 30:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/56\">",
"      Eroglu E, D'hooge J, Herbots L, et al. Comparison of real-time tri-plane and conventional 2D dobutamine stress echocardiography for the assessment of coronary artery disease. Eur Heart J 2006; 27:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/57\">",
"      Fragasso G, Lu C, Dabrowski P, et al. Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. J Am Coll Cardiol 1999; 34:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/58\">",
"      Kawano H, Fujii H, Motoyama T, et al. Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography. Am J Cardiol 2000; 85:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/59\">",
"      Elhendy A, Cornel JH, Roelandt JR, et al. Relation between contractile response of akinetic segments during dobutamine stress echocardiography and myocardial ischemia assessed by simultaneous thallium-201 single-photon emission computed tomography. Am J Cardiol 1996; 77:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/60\">",
"      Elhendy A, yan Domburg RT, Roelandt JR, et al. Accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery stenosis in patients with myocardial infarction: the impact of extent and severity of left ventricular dysfunction. Heart 1996; 76:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/61\">",
"      Cortigiani L, Picano E, Landi P, et al. Value of pharmacologic stress echocardiography in risk stratification of patients with single-vessel disease: a report from the Echo-Persantine and Echo-Dobutamine International Cooperative Studies. J Am Coll Cardiol 1998; 32:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/62\">",
"      Pingitore A, Picano E, Varga A, et al. Prognostic value of pharmacological stress echocardiography in patients with known or suspected coronary artery disease: a prospective, large-scale, multicenter, head-to-head comparison between dipyridamole and dobutamine test. Echo-Persantine International Cooperative (EPIC) and Echo-Dobutamine International Cooperative (EDIC) Study Groups. J Am Coll Cardiol 1999; 34:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/63\">",
"      Marwick TH, Case C, Sawada S, et al. Prediction of mortality using dobutamine echocardiography. J Am Coll Cardiol 2001; 37:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/64\">",
"      Steinberg EH, Madmon L, Patel CP, et al. Long-term prognostic significance of dobutamine echocardiography in patients with suspected coronary artery disease: results of a 5-year follow-up study. J Am Coll Cardiol 1997; 29:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/65\">",
"      Marcovitz PA, Shayna V, Horn RA, et al. Value of dobutamine stress echocardiography in determining the prognosis of patients with known or suspected coronary artery disease. Am J Cardiol 1996; 78:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/66\">",
"      Bigi R, Desideri A, Galati A, et al. Incremental prognostic value of stress echocardiography as an adjunct to exercise electrocardiography after uncomplicated myocardial infarction. Heart 2001; 85:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/67\">",
"      Krivokapich J, Child JS, Walter DO, Garfinkel A. Prognostic value of dobutamine stress echocardiography in predicting cardiac events in patients with known or suspected coronary artery disease. J Am Coll Cardiol 1999; 33:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/68\">",
"      Schinkel AF, Bax JJ, Elhendy A, et al. Long-term prognostic value of dobutamine stress echocardiography compared with myocardial perfusion scanning in patients unable to perform exercise tests. Am J Med 2004; 117:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/69\">",
"      Poldermans D, Fioretti PM, Boersma E, et al. Long-term prognostic value of dobutamine-atropine stress echocardiography in 1737 patients with known or suspected coronary artery disease: A single-center experience. Circulation 1999; 99:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/70\">",
"      Smart SC, Dionisopoulos PN, Knickelbine TA, et al. Dobutamine-atropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction. J Am Coll Cardiol 1999; 33:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/71\">",
"      Elhendy A, Schinkel AF, Bax JJ, et al. Prognostic value of dobutamine stress echocardiography in patients with normal left ventricular systolic function. J Am Soc Echocardiogr 2004; 17:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/72\">",
"      Marwick TH, Case C, Poldermans D, et al. A clinical and echocardiographic score for assigning risk of major events after dobutamine echocardiograms. J Am Coll Cardiol 2004; 43:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/73\">",
"      Chaowalit N, Arruda AL, McCully RB, et al. Dobutamine stress echocardiography in patients with diabetes mellitus: enhanced prognostic prediction using a simple risk score. J Am Coll Cardiol 2006; 47:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/74\">",
"      Elhendy A, Biagini E, Schinkel AF, et al. Clinical and prognostic implications of angina pectoris developing during dobutamine stress echocardiography in the absence of inducible wall motion abnormalities. Am J Cardiol 2005; 96:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/75\">",
"      Arruda AL, Barretto RB, Shub C, et al. Prognostic significance of ST-segment elevation during dobutamine stress echocardiography. Am Heart J 2006; 151:744.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/76\">",
"      Tsutsui JM, Elhendy A, Anderson JR, et al. Prognostic value of dobutamine stress myocardial contrast perfusion echocardiography. Circulation 2005; 112:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/77\">",
"      Smart SC, Knickelbine T, Malik F, Sagar KB. Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. Circulation 2000; 101:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/78\">",
"      Picano E, Marini C, Pirelli S, et al. Safety of intravenous high-dose dipyridamole echocardiography. The Echo-Persantine International Cooperative Study Group. Am J Cardiol 1992; 70:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/79\">",
"      Previtali M, Lanzarini L, Fetiveau R, et al. Comparison of dobutamine stress echocardiography, dipyridamole stress echocardiography and exercise stress testing for diagnosis of coronary artery disease. Am J Cardiol 1993; 72:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/80\">",
"      Cortigiani L, Lombardi M, Michelassi C, et al. Significance of myocardial ischemic electrocardiographic changes during dipyridamole stress echocardiography. Am J Cardiol 1998; 82:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/81\">",
"      Djordjevic-Dikic AD, Ostojic MC, Beleslin BD, et al. High dose adenosine stress echocardiography for noninvasive detection of coronary artery disease. J Am Coll Cardiol 1996; 28:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/52/27466/abstract/82\">",
"      Marwick T, Willemart B, D'Hondt AM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 1993; 87:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5300 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27466=[""].join("\n");
var outline_f26_52_27466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRESS TEST OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Comparison of test performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Prediction of event-free survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Summary and ACC/AHA guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXERCISE ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use for diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Exercise level",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Impact of timing of image acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Use for prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - With other exercise data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Special settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hypertensive response to exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prior MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DOBUTAMINE STRESS ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Addition of atropine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Use for diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Variant angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Akinetic segments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Use for prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - With other stress test data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - With induced angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - With ST elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - With contrast echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Special settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      VASODILATOR STRESS ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5300\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5300|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/52/27470\" title=\"algorithm 1\">",
"      Choice stress test modality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/60/24512\" title=\"algorithm 2\">",
"      Algorithm ETT angio chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5300|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5102\" title=\"figure 1\">",
"      Stress echocardiography outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/10/7342\" title=\"figure 2\">",
"      Hemodynamic responses during dobutamine infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/57/23454\" title=\"figure 3\">",
"      Pharmacologic echo outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/59/24510\" title=\"figure 4A\">",
"      Dobutamine echo mortality-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/59/29630\" title=\"figure 4B\">",
"      Dobutamine echo mortality-II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5300|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/3/27707\" title=\"table 1\">",
"      Performance pharm stress tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/8/6284\" title=\"table 2\">",
"      Pretest probability of CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/42/18093\" title=\"table 3A\">",
"      ACC AHA choice imaging CHD diagnosis able to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33516\" title=\"table 3B\">",
"      ACC AHA choice imaging risk I",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2998?source=related_link\">",
"      Exercise in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=related_link\">",
"      Protocols for stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41048?source=related_link\">",
"      Stress echocardiography: Indications, imaging techniques and safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_52_27467="Marrow asp bx available tests";
var content_f26_52_27467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Available tests: bone marrow aspirates and biopsies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Standard tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirate smear/ particle crush smear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buffy coat smear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow biopsy section",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron stain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clot section",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other tests applied selectively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reticulin and/or collagen stains for suspected fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enzyme cytochemical stains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunophenotyping/ flow cytometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytogenetic analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluorescence in situ hybridization (FISH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molecular genetic analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Culture for mycobacteria, leishmania, histoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acid fast staining for mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congo Red stain for suspected amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cell culture assays",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27467=[""].join("\n");
var outline_f26_52_27467=null;
var title_f26_52_27468="Mismatches consistent with nonpaternity";
var content_f26_52_27468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mismatches consistent with nonpaternity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Genetic marker",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mother",
"      </td>",
"      <td class=\"subtitle1\">",
"       Child",
"      </td>",
"      <td class=\"subtitle1\">",
"       Alleged father",
"      </td>",
"      <td class=\"subtitle1\">",
"       Paternity index",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       vWA",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       19, 18",
"      </td>",
"      <td>",
"       16, 19",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FGA",
"      </td>",
"      <td>",
"       24, 22",
"      </td>",
"      <td>",
"       22, 25",
"      </td>",
"      <td>",
"       21, 23",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D8S1179",
"      </td>",
"      <td>",
"       13, 15",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       10, 14",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D18S51",
"      </td>",
"      <td>",
"       13, 14",
"      </td>",
"      <td>",
"       14, 18",
"      </td>",
"      <td>",
"       18, 12",
"      </td>",
"      <td>",
"       8.33",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D21S11",
"      </td>",
"      <td>",
"       27, 30",
"      </td>",
"      <td>",
"       27, 29",
"      </td>",
"      <td>",
"       32, 32.2",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D19S433",
"      </td>",
"      <td>",
"       13.2, 14",
"      </td>",
"      <td>",
"       14, 13",
"      </td>",
"      <td>",
"       14, 15.2",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D16S539",
"      </td>",
"      <td>",
"       10, 11",
"      </td>",
"      <td>",
"       11, 12",
"      </td>",
"      <td>",
"       12, 13",
"      </td>",
"      <td>",
"       3.24",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D2S1338",
"      </td>",
"      <td>",
"       17, 20",
"      </td>",
"      <td>",
"       20, 23",
"      </td>",
"      <td>",
"       21, 23",
"      </td>",
"      <td>",
"       1.23",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       THO1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       6, 9.3",
"      </td>",
"      <td>",
"       6, 9",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D3S1358",
"      </td>",
"      <td>",
"       17, 16",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       18, 17",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"5\" rowspan=\"1\">",
"       Combined paternity index: 0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"5\" rowspan=\"1\">",
"       Probability of paternity: 0 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This man is not the child's biological father. The alleged father lacks the genetic markers that must be contributed to the child by the biological father. The observed nonmatching alleles (7) are at the loci listed above with a paternity index equal to zero. A minimum of three mismatches between the child and the tested man are required for the diagnosis of nonpaternity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27468=[""].join("\n");
var outline_f26_52_27468=null;
var title_f26_52_27469="Systolic BP in type 2 diabetes";
var content_f26_52_27469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lower systolic pressure is associated with fewer complications in T2DM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 3642 patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study (UKPDS), there was an inverse correlation between the updated mean systolic blood pressure and the aggregate end point for any complication related to diabetes (myocardial infarction, sudden death, angina, stroke, renal failure, lower extremity amputation or death from peripheral vascular disease, death from hyperglycemia or hypoglycemia, heart failure, vitreous hemorrhage, retinal photocoagulation, and cataract extraction). The lowest risk occurred at a systolic pressure below 120 mmHg. The values, adjusted for age, sex, and ethnic group, are expressed for white men aged 50 to 54 years at diagnosis with a mean duration of diabetes of ten years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Adler AI, Stratton IM, Neil HA, et al. BMJ 2000; 321:412.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27469=[""].join("\n");
var outline_f26_52_27469=null;
var title_f26_52_27470="Choice stress test modality";
var content_f26_52_27470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choice of exercise testing modality in different clinical settings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 406px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Marked baseline ECG abnormalities\" include pre-excitation (Wolff-Parkinson-White) syndrome, more than 1 mm of ST depression at rest, and patients taking digoxin or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression. Evaluation of patients with left bundle branch block or paced ventricular rhythm is not included in this algorithm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27470=[""].join("\n");
var outline_f26_52_27470=null;
var title_f26_52_27471="Pathogenesis of LPG";
var content_f26_52_27471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Summary and proposed mechanisms of LPG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 488px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Saito, T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_52_27471=[""].join("\n");
var outline_f26_52_27471=null;
